

**P** = All posters are available as electronic version at the terminals on the 3<sup>rd</sup> level (room 3C+D).

**\*P** = Posters marked with \* are nominated for a poster award and will be presented additionally on a poster wall within the poster exhibition on the 3<sup>rd</sup> level (room 3C+D).

## SY I: GLOBAL SPREAD OF RESISTANCE

### P 1

**Analyse des Antibiotikaverbrauchs am Kinderklinikum der Technischen Universität Munich: Angriffspunkte für ein Antibiotic Stewardship Programm**

*M. Burggraf*<sup>1</sup>, *J. Geisberger*, *K. Kreitmeyer*, *J. Berndt*, *M. Steinhauser*, *N. Rieber*, *U. Behrends*, *J. Hübner*, Munich

### \*P 2

**Intratracheal application of a lytic phage against *Acinetobacter baumannii* pneumonia in mice**

*S.-M. Wienhold*<sup>1</sup>, *M. Brack*<sup>1</sup>, *G. Nouailles*<sup>1</sup>, *N. Suttorp*<sup>1</sup>, *C. Seitz*<sup>2</sup>, *A. Ross*<sup>2</sup>, *H. Ziehr*<sup>2</sup>, *K. Dieterl*<sup>1</sup>, *A. Gruber*<sup>1</sup>, *M. Rohde*<sup>2</sup>, *C. Rohde*<sup>2</sup>, *M. Witzenth*<sup>1</sup>, <sup>1</sup>Berlin, <sup>2</sup>Braunschweig

### \*P 3

**Characterisation of *Neisseria gonorrhoeae* isolates using a core-genome MLST scheme**

*P. Higgins*<sup>1</sup>, *J. Ertel*<sup>1</sup>, *M. Fabri*<sup>1</sup>, *C. Lehmann*<sup>1</sup>, *M. Parcina*<sup>1,2</sup>, *C. Schwarze-Zander*<sup>1,2</sup>, *H. Seifert*<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Bonn

### P 4

**Outcomes of isoniazid resistant TB in patients in Nepal**

*F. Freinberger*<sup>1</sup>, *H. Hoffmann*<sup>2</sup>, *K. Avsar*<sup>2</sup>, *B. Maharjan*<sup>3</sup>, *D. Pradhan*<sup>3</sup>, *B. Shrestha*<sup>3</sup>, *J. Rupp*<sup>4</sup>, *K. Kranzer*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Gauting, <sup>3</sup>Kathmandu/Nepal, <sup>4</sup>Lübeck

### \*P 5

**Genetic variation and overwintering of *Aedes albopictus* populations from Germany**

*A. Heitmann*<sup>1</sup>, *R. Lühken*<sup>1</sup>, *S. Jansen*<sup>1,2</sup>, *J. Schmidt-Chanasit*<sup>1,2</sup>, *J. Börstler*<sup>1</sup>, *D. Walther*<sup>3</sup>, *H. Kampen*<sup>4</sup>, *B. Pluskota*<sup>5</sup>, *I. Ferstl*<sup>6</sup>, *A. Jöst*<sup>5</sup>, *N. Becker*<sup>5,6</sup>, *E. Tannich*<sup>1,2</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Hamburg-Luebeck-Borstel, <sup>3</sup>Muencheberg, <sup>4</sup>Greifswald, <sup>5</sup>Speyer, <sup>6</sup>Heidelberg

### P 6

**Toward Validating the Pathoblocker Concept: Lead Generation and Optimization of PqsR Antagonists for the Treatment of Chronic *Pseudomonas aeruginosa* Infections**

*M. Emptyng*, *C. Lu*, *C. Maurer*, *M. Zender*, *A. Thomann*, *A. de Mello Martins*, *R. Hartmann*, Saarbrücken

### P 7

***Mycoplasma genitalium* demonstrates high levels of antibiotic resistance in Australia**

*S. Bone*<sup>1</sup>, *L. Tan*<sup>1</sup>, *S. Walker*<sup>1</sup>, *J. Su*<sup>2</sup>, *C. Bradshaw*<sup>2</sup>, *C. Fairley*<sup>2</sup>, *S. Garland*<sup>2</sup>, *E. Mokany*<sup>1</sup>, *S. Tabrizi*<sup>2</sup>, <sup>1</sup>Sydney/Australia, <sup>2</sup>Melbourne/Australia

### P 8

**cfr-Gen vermittelte Mehrfachresistenz bei Staphylokokken aus dem Nutztiersektor und das Risiko der Übertragung auf den Menschen**

*C. Cuny*<sup>1</sup>, *W. Witte*<sup>1</sup>, *P. Arnold*<sup>2</sup>, <sup>1</sup>Wernigerode, <sup>2</sup>Echternach/Luxembourg

### \*P 9

**A retrospective analysis of paediatric inpatient data on antibiotic use in a teaching hospital in The Gambia**

*P. Chaw*<sup>1,2</sup>, *K. Schlinkmann*<sup>1,2</sup>, *H. Raupach-Rosin*<sup>1</sup>, *A. Karch*<sup>1,2</sup>, *J. Hübner*<sup>3</sup>, *R. Mikolajczyk*<sup>1,4</sup>, <sup>1</sup>Braunschweig, <sup>2</sup>Hanover, <sup>3</sup>Munich, <sup>4</sup>Halle (Saale)

### P 10

**Emergence of ceftazidime-avibactam non-susceptibility in a multidrug resistant *Klebsiella pneumoniae* isolate**

*A. Both*, *H. Büttner*, *J. Huang*, *M. Perbandt*, *C. Belmar Campos*, *M. Christner*, *F. Maurer*, *S. Kluge*, *C. König*, *M. Aepfelbacher*, *D. Wichmann*, *H. Rohde*, Hamburg

### \*P 11

**Highly conserved plasmids drive the spread of the mobile colistin resistance gene *mcr-1* in Germany and Spain**

*L. Falgenhauer*<sup>1</sup>, *Y. Yao*<sup>1</sup>, *H. Ghosh*<sup>1</sup>, *S. Doijad*<sup>1</sup>, *S.-E. Waezsada*<sup>1</sup>, *K. Gwozdziński*<sup>1</sup>, *J. Schmiedel*<sup>1</sup>, *M. Fritzenwanker*<sup>1</sup>, *N. Roschanski*<sup>2</sup>, *U. Roesler*<sup>2</sup>, *A. Irrgang*<sup>2</sup>, *A. Käsbohrer*<sup>2,3</sup>, *R. Bauerfeind*<sup>1</sup>, *C. Ewers*<sup>4</sup>, *A. Schiffmann*<sup>1</sup>, *G. Michael*<sup>5</sup>, *S. Schwarz*<sup>2</sup>, *B. Bunk*<sup>4</sup>, *C. Spröer*<sup>4</sup>, *A. Goemann*<sup>1</sup>, *J. Overmann*<sup>4</sup>, *N. Prim*<sup>5</sup>, *A. Rivera*<sup>5</sup>, *B. Mirelis*<sup>5</sup>, *C. Imirzalioglu*<sup>1</sup>, *T. Chakraborty*<sup>1</sup>, <sup>1</sup>Giessen, <sup>2</sup>Berlin, <sup>3</sup>Vienna/Austria, <sup>4</sup>Braunschweig, <sup>5</sup>Barcelona/Spain

### P 12

**Comparative analysis of ESBL-producing *E. coli* isolated from environment, fish, livestock and humans in Mwanza/Tanzania**

*S. Mshana*<sup>1</sup>, *L. Falgenhauer*<sup>2</sup>, *N. Moremi*<sup>1</sup>, *J. Seni*<sup>1</sup>, *H. Ghosh*<sup>2</sup>, *C. Imirzalioglu*<sup>2</sup>, *T. Chakraborty*<sup>2</sup>, <sup>1</sup>Mwanza/Tanzania, <sup>2</sup>Gießen

### \*P 13

**Rapid identification of carbapenem-resistant *Acinetobacter baumannii* with a novel immunochromatographic lateral flow assay**

*S. Mertens*<sup>1</sup>, *P. Higgins*<sup>1</sup>, *Q. Gillemann*<sup>2</sup>, *P. Mertens*<sup>2</sup>, *H. Seifert*<sup>1</sup>, *M. Krönke*<sup>1</sup>, *A. Klimka*<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Gembloux/Belgium

### P 14

**Biosynthesis of capsular polysaccharides as target for antibiotics**

*M. Rausch*, *H. Ulm*, *H.-G. Sahl*, *F. Grein*, *T. Schneider*, Bonn

### \*P 15

**Rapid emergence of highly variable and transferable oxazolidinone and phenicol transporter *OprA* in German clinical *Enterococcus* spp.**

*J. Bender*, *C. Fleige*, *D. Lange*, *U. Geringer*, *I. Klare*, *G. Werner*, Wernigerode

**P 16****ASA<sup>3</sup>P: An automatic and highly scalable pipeline for bacterial genome assembly, annotation and higher-level analyses**

*O. Schwengers, M. Schneider, A. Hoek, Y. Yao, H. Ghosh, M. Fritzenwanker, S. Doijad, L. Falgenhauer, T. Hain, T. Chakraborty, A. Goesmann, Gießen*

**P 17****A novel medium for the improved detection of *mcr-1*-producing *Enterobacteriaceae***

*K. Gwozdziński, L. Falgenhauer, C. Imirzalioglu, T. Chakraborty, Gießen*

**P 18****Molecular epidemiology of multidrug resistant tuberculosis in Germany 1995-2016**

*M. Merker<sup>1</sup>, T. Kohl<sup>1</sup>, R. Diehl<sup>2</sup>, S. Andres<sup>1</sup>, C. Lange<sup>1</sup>, K. Kranzer<sup>1</sup>, S. Niemann<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Kiel*

**P 19****HCV Resistance Profile Evolution in a GT1b, DAA-naïve Patient before, on and after Failing Triple DAA Therapy**

*E. Knops<sup>1</sup>, N. Schübel<sup>2</sup>, E. Heger<sup>1</sup>, R. Kaiser<sup>1</sup>, S. Inden<sup>1</sup>, P. Kalaghatg<sup>3</sup>, S. Sierra<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Osnabrück, <sup>3</sup>Saarbrücken*

**P 20****A novel subclone of ST131 C1/H30R harboring *bla*<sub>CTX-M-27</sub> in clinical isolates emerging in Germany**

*H. Ghosh, S. Doijad, L. Falgenhauer, M. Fritzenwanker, O. Schwengers, C. Imirzalioglu, T. Chakraborty, Contain Study Group, RESET Study Group, Giessen*

**P 21****Selten, aber divers - *cf*-vermittelte Linezolidresistenz bei *S. aureus***

*F. Layer<sup>1</sup>, C. Kehrenberg<sup>2</sup>, J. Bender<sup>1</sup>, G. Werner<sup>1</sup>, B. Strommenger<sup>1</sup>, <sup>1</sup>Wernigerode, <sup>2</sup>Hanover*

**\*P 22****Ebola Virus persistence in seminal fluid of Ebola virus disease survivors: a longitudinal study and evidence for sexual transmission during the resurgence of the disease in Guinea in 2016**

*S. Duraffour<sup>1</sup>, D. Sissoko<sup>2</sup>, B. Diallo<sup>3</sup>, R. Kerber<sup>1</sup>, L. Oestereich<sup>1</sup>, J. Guedj<sup>4</sup>, T. Nguyen<sup>4</sup>, P. Formenty<sup>5</sup>, S. Keita<sup>3</sup>, D. Malvy<sup>2</sup>, X. Anglaret<sup>2,6</sup>, S. Günther<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Bordeaux/France, <sup>3</sup>Conakry/Guinea, <sup>4</sup>Paris/France, <sup>5</sup>Geneva/Switzerland, <sup>6</sup>Abidja/Côte d'Ivoire*

**P 23****Molecular characterization of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in asylum-seekers in Rhineland-Palatinate, 2016-2017**

*Y. Pfeifer<sup>1</sup>, L. Ehlkes<sup>2,3,4</sup>, G. Werner<sup>1</sup>, T. Eckmanns<sup>3</sup>, M. Vogt<sup>2</sup>, P. Zanger<sup>2,5</sup>, J. Walter<sup>3</sup>, <sup>1</sup>Wernigerode, <sup>2</sup>Landau, <sup>3</sup>Berlin, <sup>4</sup>Stockholm/Sweden, <sup>5</sup>Heidelberg*

**P 24****Pathogens and antimicrobial resistance in patients with travelers' diarrhea presenting at a German tertiary care center.**

*T. Brehm, M. Addo, T. Rolling, C. Vinnemeier, Hamburg*

**SY II: NOVEL ANTIVIRAL TREATMENT STRATEGIES****P 25****Resident alveolar macrophages are depleted early upon influenza virus infection and cell death correlates positively with neutrophil recruitment**

*C. Malainou, C. Peteranderl, W. Seeger, J. Lohmeyer, S. Herold, Gießen*

**\*P 26****Antiretroviral Treatment Initiation and Guideline Adherence in the German ClinSurv HIV Cohort between 1999-2016: Assessing the Impact of the START Trial in Germany**

*M. Stecher<sup>1</sup>, D. Schmidt<sup>2</sup>, C. Kollan<sup>2</sup>, B. Günsenheimer-Bartmeyer<sup>2</sup>, C. Lehmann<sup>1</sup>, M. Platten<sup>1</sup>, G. Fätkenheuer<sup>1</sup>, J. Vehreschild<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Berlin*

**\*P 27****IFN-free DAA therapy does not fully re-constitute the altered phenotype and function of HCV-specific CD8+ T cells but immune check-point inhibitions can selectively re-invigorate the functionality during chronic HCV**

*A. Aregay, K. Deterding, M. Manns, M. Cornberg, S. Owusu Sekyere, H. Wedemeyer, Hanover*

**P 28****A new antiviral approach – Inhibition of RNA viruses depending on eIF4A-dependent translation by the natural compound Silvestrol**

*C. Müller<sup>1</sup>, F. Schulte<sup>2</sup>, N. Biedenkopf<sup>2</sup>, S. Becker<sup>2</sup>, J. Ziebuhr<sup>1</sup>, R. Hartmann<sup>2</sup>, A. Grünweller<sup>2</sup>, <sup>1</sup>Gießen, <sup>2</sup>Marburg*

**P 29****Suppressive capacity of PMN-MDSC is lost in advanced stages of HIV-1 infection**

*E. Grütznert, A. Neizert, R. Stirner, R. Conca, I. Andrä, M. Schiemann, C. Klein, U. Protzer, J. Bogner, R. Draenert, Munich*

**\*P 30****Establishment of a single-point assay to evaluate the relationship of molecular structure and antiviral activity of cationic amphiphilic drugs**

*A.-P. Gunesch<sup>1</sup>, F. Zapatero-Belinchon<sup>1</sup>, M. Manns<sup>1</sup>, E. Steinmann<sup>1</sup>, M. Brönstrup<sup>2</sup>, T. von Hahn<sup>1</sup>, <sup>1</sup>Hanover, <sup>2</sup>Braunschweig*

**\*P 31****Different prevalences of HCV resistance-associated substitutions within NS5A of genotype 4 and implications for treatment**

*J. Dietz<sup>1</sup>, S. Susser<sup>1</sup>, J. Vermehren<sup>1</sup>, K.-H. Peiffer<sup>1</sup>, T. Welzel<sup>1</sup>, B. Müllhaupt<sup>2</sup>, K. Wursthorn<sup>3</sup>, J. Petersen<sup>3</sup>, J. Schattenberg<sup>4</sup>, J.-P. Chave<sup>5</sup>, C. Niederau<sup>6</sup>, R. Schmid<sup>7</sup>, J. von Felden<sup>3</sup>, J. Schulze zur Wiesch<sup>8</sup>, C. Moreno<sup>9</sup>, T. von Hahn<sup>9</sup>, T. Berg<sup>10</sup>, C. Berg<sup>11</sup>, S. Zeuzem<sup>1</sup>, C. Sarrazin<sup>1,12</sup>, <sup>1</sup>Frankfurt am Main, <sup>2</sup>Zürich/Switzerland, <sup>3</sup>Hamburg, <sup>4</sup>Mainz, <sup>5</sup>Lausanne/Switzerland, <sup>6</sup>Oberhausen, <sup>7</sup>Munich, <sup>8</sup>Brüssel/Belgium, <sup>9</sup>Hanover, <sup>10</sup>Leipzig, <sup>11</sup>Tübingen, <sup>12</sup>Wiesbaden*

**P 32****West Nile virus and Usutu virus monitoring of wild birds in Germany**

*F. Michel*<sup>1</sup>, *U. Ziegler*<sup>1</sup>, *M. Eiden*<sup>1</sup>, *M. Keller*<sup>1</sup>, *C. Fast*<sup>1</sup>, *G. Dobler*<sup>2</sup>, *M. Groschup*<sup>1</sup>, <sup>1</sup>Greifswald-Insel Riems, <sup>2</sup>Munich

**\*P 33****Sensitizing *Staphylococcus aureus* to cationic anti-microbial peptides**

*A. Jorge*<sup>1</sup>, *U. Bilitewski*<sup>2,3</sup>, *A. Peschel*<sup>1</sup>, <sup>1</sup>Tübingen, <sup>2</sup>Braunschweig, <sup>3</sup>Hanover

**P 34****Host proteases as potential target for anti-viral therapy to influenza A infections**

*K. Schughart*<sup>1,2,3</sup>, *R. Lambert*<sup>1,2</sup>, <sup>1</sup>Braunschweig, <sup>2</sup>Hanover, <sup>3</sup>Memphis/USA

**P 35****Enabling anti-viral adoptive T cell therapy from seronegative individuals**

*T. Müller*, *M. Effenberger*, *K. Schober*, *D. Busch*, Munich

**P 36****Modulation of the host cell response to treat Lassa Fever**

*L. Oestereich*, *D. Wozniak*, *E. Pallasch*, *S. Bockholt*, *C. Munoz-Fontela*, *S. Günther*, Hamburg

**\*P 37****Targeted AAV-mediated Delivery of HIV-1 LTR-specific Recombinase Brec1**

*J. Breuer*<sup>1</sup>, *N. Beschorner*<sup>2</sup>, *J. Hauber*<sup>2</sup>, *H. Büning*<sup>1</sup>, *F. Buchholz*<sup>3</sup>, <sup>1</sup>Hanover, <sup>2</sup>Hamburg, <sup>3</sup>Dresden

**P 38****Development of small molecule inhibitors targeting TRAF protein binding to the LMP1 oncoprotein of Epstein-Barr virus**

*F. Giehler*<sup>1</sup>, *D. Weid*<sup>2</sup>, *M. Ostertag*<sup>1</sup>, *K. Schorpp*<sup>1</sup>, *S. Dornauer*<sup>1</sup>, *H. Kutz*<sup>1</sup>, *K. Sterz*<sup>1</sup>, *B. Biesinger-Zwosta*<sup>2</sup>, *K. Hadian*<sup>1</sup>, *J. Kirchmair*<sup>3</sup>, *G. Popowicz*<sup>3</sup>, *A. Kieser*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Erlangen, <sup>3</sup>Hamburg

**\*P 39****Assessing off-target activity of a novel TALEN targeting the HIV co-receptor CCR5**

*L. Schwarze*, *U. Mock*, *B. Fehse*, Hamburg

**\*P 40****High throughput reporter screen to identify inhibitors of clinically relevant human polyomavirus infections**

*E. Kraus*, *N. Fischer*, *A. Grundhoff*, Hamburg

**\*P 41****Non-immunosuppressive cyclosporin A derivatives as broad-spectrum coronavirus inhibitors**

*D. Bairad*<sup>1</sup>, *S. Schwinghammer*<sup>1</sup>, *Y. Ma-Lauer*<sup>1</sup>, *B. von Brunn*<sup>1</sup>, *M. Müller*<sup>2</sup>, *D. Muth*<sup>2,3</sup>, *C. Drosten*<sup>2,3</sup>, *A. von Brunn*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Bonn, <sup>3</sup>Berlin

**P 42****Screening for antivirals targeting the human cytomegalovirus alkaline nuclease using a high-throughput system**

*T. Potgieter*, *A. Caceres-Nuñez*, *E. Ostermann*, *W. Brune*, Hamburg

**P 43****Analysis of the IFN-alpha treatment response, HCC risk and mortality of HDV infected patients at different levels of HDV replication**

*J.-H. Bockmann*<sup>1</sup>, *M. Lütgehetmann*<sup>1</sup>, *J. Blöcker*<sup>1</sup>, *J. Von Felden*<sup>1</sup>, *M. Wehmeyer*<sup>1</sup>, *K. Giersch*<sup>1</sup>, *C. Scheurich*<sup>1</sup>, *M. Dandri*<sup>1</sup>, *S. Lüth*<sup>2</sup>, *A. Lohse*<sup>1</sup>, *J. Schulze zur Wiesch*<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Neuruppin

**P 44****Chronische Norovirusinfektionen nach Nierentransplantation - Risikofaktoren und Therapieoption mit Immunglobulinen**

*C. Struve*, *A. Bienholz*, *S. Doff*, *U. Eisenberger*, *J. Korth*, *B. Wilde*, *O. Witzke*, *H. Guberina*, Essen

**\*P 45****Decision Making of Accurate HIV-1 Post Exposure Prophylaxis Prescription**

*M. Scholten*, *I. Suárez*, *D. Gillor*, *M. Platten*, *T. Kümmerle*, *G. Fätkenheuer*, *C. Lehmann*, Cologne

**P 46****Human cytomegalovirus infections after Hematopoietic Stem Cell Transplantation: correlation of serum cytokine levels and variations in the HCMV genome population with clinical outcomes**

*P. Kay-Fedorov*, *P. Varanasi*, *J. Zischke*, *A. Dhingra*, *A. Heim*, *C. Falk*, *E. Mischak-Weissing*, *T. Ganzenmüller*, Hanover

**P 47****Crystal structure of Zika virus NS2B-NS3 protease facilitates design of antivirals**

*R. Hilgenfeld*<sup>1</sup>, *L. Zhang*<sup>1</sup>, *G. Hansen*<sup>1</sup>, *C. Nitsche*<sup>2</sup>, *C. Klein*<sup>2</sup>, *W. Rut*<sup>3</sup>, *M. Drag*<sup>3</sup>, *J. Lei*<sup>1</sup>, <sup>1</sup>Lübeck, <sup>2</sup>Heidelberg, <sup>3</sup>Wroclaw/Poland

**P 48****alpha-Ketoamides as broad spectrum inhibitors of coronavirus and enterovirus replication**

*L. Zhang*<sup>1</sup>, *D. Lin*<sup>1</sup>, *Y. Kusov*<sup>1</sup>, *Q. Ma*<sup>1</sup>, *Y. Nian*<sup>2</sup>, *J. Wang*<sup>2</sup>, *H. Liu*<sup>2</sup>, *P. Leyssen*<sup>3</sup>, *K. Lanko*<sup>3</sup>, *J. Neyts*<sup>3</sup>, *A. de Wilde*<sup>4</sup>, *E.J. Snijder*<sup>4</sup>, *R. Hilgenfeld*<sup>1</sup>, <sup>1</sup>Lübeck, <sup>2</sup>Shanghai/China, <sup>3</sup>Leuven/Belgium, <sup>4</sup>Leiden/Netherlands

**SY III: IMMUNOTHERAPIES AND VACCINES****P 49****Partial depletion of regulatory T cells improve the immune response after vaccination against tuberculosis**

*F. Varela*<sup>1</sup>, *I. Ogunsulire*<sup>1</sup>, *J. Behrends*<sup>1</sup>, *E.-M. Agger*<sup>2</sup>, *M. Almanan*<sup>3</sup>, *D. Hildeman*<sup>3</sup>, *C. Hölscher*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Copenhagen/Denmark, <sup>3</sup>Cincinnati/USA

**P 50****Interleukin-23 promotes the recruitment of protective multifunctional CD4 T cells after subunit *Mycobacterium tuberculosis* vaccination independently of interleukin-17A**

*K. Ritter*<sup>1</sup>, *J. Behrends*<sup>1</sup>, *E.-M. Agger*<sup>2</sup>, *C. Hölscher*<sup>1,3</sup>, *H. Erdmann*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Copenhagen/Denmark, <sup>3</sup>Kiel

P 51

**A novel QuantiFERON based test for detection of neutralizing IFN- $\gamma$  autoantibodies in patients with severe opportunistic infections***I. Suarez, C. Lehmann, H. Gröll, J. Gräß, M. Kochanek, G. Fätkenheuer, G. Plum, P. Hartmann, J. Rybniker, Cologne*

\*P 52

**Reconstitution of HIV-, MTB- and CMV-specific T-cell functionality in children on antiretroviral therapy is associated with shifts in memory phenotype and decreased PD1-expression***M. Muenchhoff<sup>1</sup>, E. Adland<sup>2</sup>, T. Ndung'u<sup>3</sup>, P. Goulder<sup>2,3</sup>, <sup>1</sup>Munich, <sup>2</sup>Oxford/United Kingdom, <sup>3</sup>Durban/South Africa*

P 53

**Sensitizing Staphylococcus aureus to cationic antimicrobial peptides by MprF-inhibiting monoclonal antibodies***C. Slavetinsky<sup>1</sup>, C. Ernst<sup>1</sup>, A. Kraus<sup>2</sup>, A. Geyer<sup>1</sup>, A. Peschel<sup>1</sup>, <sup>1</sup>Tübingen, <sup>2</sup>Martinsried*

P 54

**Duration of protection from pneumonia and antibody kinetics in pneumococcal vaccination of hemodialysis patients (DOPPIO)***S. Mellinghoff, V. Dimitriou, A. Steinbach, G. von Gersdorff, B. Liss, O. Cornely, Cologne*

P 55

**Whole cell lysate as antigen source for the differential analysis of experimental vaccines against newly emerging infections***O. Pinkenburg<sup>1</sup>, V. Czudai-Matwich<sup>1</sup>, A. Fiedler<sup>2</sup>, M. Mühlebach<sup>2</sup>, M. Matrosovich<sup>1</sup>, S. Becker<sup>1</sup>, M. Lohoff<sup>1</sup>, <sup>1</sup>Marburg, <sup>2</sup>Langen*

P 56

**Immunogenetics of Ebola virus disease***P. Ruibal<sup>1</sup>, A. Lüdtker<sup>1</sup>, L. Oestereich<sup>1</sup>, B. Becker-Ziaja<sup>1</sup>, S. Gómez-Medina<sup>1</sup>, M. Rottstegge<sup>1</sup>, D.M. Wozniak<sup>1</sup>, T. Rieger<sup>1</sup>, G. Xiaojiang<sup>2,3</sup>, M. Carrington<sup>2,3</sup>, F. Feng<sup>4</sup>, K. Sawatzki<sup>2</sup>, T.B. Kepler<sup>4</sup>, S. Günther<sup>1</sup>, C. Muñoz-Fontela<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Frederick/USA, <sup>3</sup>Cambridge/USA, <sup>4</sup>Boston/USA*

\*P 57

**KIR3DS1, an activating NK cell receptor implicated in HIV-1 disease, binds differentially to distinct forms of HLA-F***A. Hölzemer<sup>1</sup>, C. Dulberger<sup>2</sup>, J. Chukwukelu<sup>1</sup>, G. Martrus Zapater<sup>1</sup>, E. Adams<sup>2</sup>, M. Altfeld<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Chicago/USA*

P 58

**Targeting novel surface associated proteins for vaccination against Staphylococcus aureus***A. Klimka, A. Nicolai, S. Mertins, F. Becker, O. Krut, M. Krönke, Cologne*

P 59

**Impact of immunosuppressive drugs on the BK-Polyomavirus Non Coding Control Region (NCCR) activity***J. Korth, B. Wilde, S. Ciesek, J. Verheyen, A. Brinkhoff, U. Dittmer, A. Kribben, O. Witzke, M. Wiedera, Essen*

P 60

**The DZIF Transplant Cohort e.V***D. Schindler, Members of the DZIF Transplantation Cohort e.V., Munich*

\*P 61

**Peptide vaccination against cytomegalovirus (CMV) induces cellular immune responses in CMV seronegative endstage renal disease patients***C. Sommerer, A. Schmitt, T. Giese, P. Schnitzler, M. Zeier, M. Schmitt, Heidelberg*

P 62

**Kidney transplant recipients show humoral response to 13-valent conjugate pneumococcal vaccine***S. Hecke, M. Lindemann, B. Wilde, P. Horn, S. Dolff, A. Bienholz, U. Eisenberger, O. Witzke, Essen*

P 63

**Modifying the ggtree Function to Visualize IgG Recognition Strength of Peptide Variants in the Context of their Phylogenetic Relationship***V. Hoffmann<sup>1</sup>, G. Pollakis<sup>2</sup>, M. Ahmed<sup>1</sup>, K. Held<sup>1</sup>, C. Geldmacher<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Liverpool/United Kingdom*

P 64

**Increased phosphorylation of p70S6 kinase is associated with CMV reactivation in lung transplant patients***M. Meier, V. Besa, M. Cherneha, S. Dolff, A. Bienholz, H. Guberina, B. Wilde, O. Witzke, Essen*

P 65

**Dual role of antigen-presenting cells during Ebola virus infection***E. Nelson<sup>1</sup>, N. Hertoghs<sup>2</sup>, A. Ludtke<sup>1</sup>, S. Gunther<sup>1</sup>, S. Krasemann<sup>1</sup>, J. Idoyaga<sup>3</sup>, L. Oestereich<sup>1</sup>, T. Geijtenbeek<sup>2</sup>, C. Muñoz-Fontela<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Amsterdam/Netherlands, <sup>3</sup>Stanford/USA*

P 66

**Associations between individual gut microbiota signatures and the activation of an adaptive immune response to anti-PD-L1 immunotherapy in patients with metastatic melanoma***A. Tsakmaklis<sup>1</sup>, R. Hartel<sup>1</sup>, M. von Bergwelt<sup>1</sup>, H. Schlösser<sup>1</sup>, M. Schlaak<sup>1</sup>, C. Mauch<sup>1</sup>, F. Farowski<sup>1</sup>, M. Cruz Aguilar<sup>1</sup>, P. Oefner<sup>2</sup>, P. Higgins<sup>1</sup>, M. Vehreschild<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Regensburg*

P 67

**Prophylactic and Therapeutic Potential of Antisera against Acute Viral Infections***R. Schmidt<sup>1</sup>, O. Dolnik<sup>2</sup>, A. Volz<sup>3</sup>, G. Sutter<sup>3</sup>, V. von Messling<sup>1</sup>, <sup>1</sup>Langen, <sup>2</sup>Marburg, <sup>3</sup>Munich*

P 68

**Experimental performance evaluation and threshold recommendations for MHC class I binding prediction tools***M. Bonsack, S. Hoppe, J. Winter, R. Blatnik, A. Riemer, Heidelberg*

\*P 69

**Cytomegalovirus reactivation prior to acute graft-versus-host disease leads to fast immune reconstitution and overall survival***P. Varanasi<sup>1</sup>, J. Ogonek<sup>1</sup>, E. Dammann<sup>1</sup>, S. Luther<sup>1</sup>, P. Schweier<sup>1</sup>, M. Stadler<sup>1</sup>, A. Ganser<sup>1</sup>, M. Messerle<sup>1</sup>, C. Falk<sup>1</sup>, S. Borchers<sup>2</sup>, L. Hambach<sup>1</sup>, E. Weissinger<sup>1</sup>, <sup>1</sup>Hanover, <sup>2</sup>Heidelberg*

P 70

**Increased expression of the coinhibitors PD-1 and BTLA on CMV-specific T-cells is associated with symptomatic CMV infection in renal transplant patients**

*B. Wilde, J. Reinold, J. Korth, M. Sun, S. Doff, A. Bienholz, C. Struve, H. Guberina, P. Horn, M. Lindemann, O. Witzke, Essen*

P 71

**Evaluation of synthetic self-replicating RNAs expressing Ebola virus proteins**

*V. Krähling<sup>1</sup>, S. Erbar<sup>2</sup>, A. Vogel<sup>2</sup>, S. Witzel<sup>2</sup>, B. Tillmann<sup>2</sup>, T. Beisser<sup>2</sup>, U. Sahin<sup>2</sup>, S. Becker<sup>1</sup>, <sup>1</sup>Marburg, <sup>2</sup>Mainz*

\*P 72

**Efficient clearance of gram-positive and negative bacteria by human iPSC derived phagocytes**

*A. Rafiei, A. Hashtchin, M. Ackermann, H. Kempf, C. Hesse, M. Bickes, M. Hetzel, M. Kühnel, A. Schambach, S. Wronski, T. Moritz, R. Zweigerdt, D. Viemann, A. Munder, N. Lachmann, Hanover*

P 73

**Eingeschränkte Wirksamkeit der quadrivalenten Meningokokken-Impfung bei Patienten mit atypischem hämolytisch-urämischem Syndrom und Therapie mit dem Komplementinhibitor Eculizumab**

*A. Bienholz<sup>1</sup>, S. Doff<sup>1</sup>, H. Guberina<sup>1</sup>, B. Wilde<sup>1</sup>, U. Vogel<sup>2</sup>, H. Claus<sup>2</sup>, A. Kribben<sup>1</sup>, O. Witzke<sup>1</sup>, <sup>1</sup>Essen, <sup>2</sup>Würzburg*

P 74

**Human miRNome profiling identifies a microRNA signature induced by the Ebola vaccine rVSV-ZEBOV**

*T. Fischer<sup>1,2</sup>, C. Dahlke<sup>1,2</sup>, M. Spohn<sup>1</sup>, L. Burkhard<sup>1</sup>, F. Olearo<sup>1</sup>, M. Ly<sup>1,2</sup>, M. Zinser<sup>1</sup>, R. Kasonta<sup>1,2</sup>, A. Rechten<sup>1,2</sup>, H. Stubbe<sup>3</sup>, S. Borregaard<sup>1</sup>, A. Jambrecina<sup>1</sup>, A. Grundhoff<sup>1</sup>, M. Addo<sup>1,2</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Hamburg-Lübeck-Borstel-Riems, <sup>3</sup>Munich*

P 75

**Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes**

*A. Volz, A. Freudenstein, L. Marr, G. Sutter, Munich*

\*P 76

**Dominant low avidity clonotypes arise from reverse TCR repertoire evolution during chronic CMV infection**

*K. Schober<sup>1</sup>, F. Voit<sup>1</sup>, S. Grassmann<sup>1</sup>, T. Müller<sup>1</sup>, J. Eggert<sup>1</sup>, L. Cicin-Sain<sup>2,3</sup>, V. Buchholz<sup>1</sup>, D. Busch<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Braunschweig, <sup>3</sup>Hanover*

\*P 77

**Immune regulatory mechanisms in acute HIV-1 infection**

*H. Stubbe<sup>1</sup>, K. Mücke<sup>1</sup>, A. Jablonka<sup>2</sup>, M. Stecher<sup>3</sup>, R. Stirner<sup>1</sup>, R. Conca<sup>1</sup>, U. Kastenbauer<sup>1</sup>, R. Pauli<sup>1</sup>, N. Postel<sup>1</sup>, C. Spinner<sup>1</sup>, E. Wolf<sup>1</sup>, G. Behrens<sup>2</sup>, J. Vehreschild<sup>3</sup>, J. Bogner<sup>1</sup>, R. Draenert<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Hanover, <sup>3</sup>Cologne*

P 78

**Development of a new strategy to target intracellular infections with *Leishmania major*: from a natural compound to synthetic derivatives**

*S. Choy<sup>1</sup>, H. Bernin<sup>1</sup>, S. Lender<sup>1</sup>, E. Bifeld<sup>1</sup>, Y. Fujimoto<sup>2</sup>, T. Aiba<sup>2</sup>, K. Fukase<sup>3</sup>, N. Gonzalez-Roldan<sup>4</sup>, J. Clos<sup>1</sup>, H. Lotter<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Yokohama/Japan, <sup>3</sup>Osaka/Japan, <sup>4</sup>Borstel*

P 79

**Humanized mice reconstituted with mature T and B cells for testing novel immune modulatory strategies against Epstein-Barr-Virus infection and lymphoma**

*S. Danisch<sup>1</sup>, A. Cornelius<sup>1</sup>, C. Slabik<sup>1</sup>, S. Theobald<sup>1</sup>, M. Albanese<sup>2</sup>, R. Zeidler<sup>2</sup>, W. Hammerschmidt<sup>2</sup>, R. Stripecke<sup>1</sup>, <sup>1</sup>Hanover, <sup>2</sup>Munich*

P 80

**Efficacy testing of a newly developed MVA-based vaccine against Ebola virus in a mouse model**

*A. Kupke<sup>1</sup>, A. Volz<sup>2</sup>, E. Dietzel<sup>1</sup>, J. Schmidt<sup>1</sup>, H. Shams-Eldin<sup>1</sup>, L. Sauerhering<sup>1</sup>, M. Gellhorn Serra<sup>1</sup>, C. Herden<sup>3</sup>, M. Eickmann<sup>1</sup>, S. Becker<sup>1</sup>, G. Sutter<sup>2</sup>, <sup>1</sup>Marburg, <sup>2</sup>Munich, <sup>3</sup>Gießen*

P 81

**HCMV infection of mice reconstituted with the human immune system reveals anatomical sites of reactivation by optical imaging analyses and modulation of T and B cell maturation in lymphatic tissues**

*S. Theobald<sup>1</sup>, V. Volk<sup>1</sup>, H. Olbrich<sup>1</sup>, S. Lienenklaus<sup>1</sup>, A. Bleich<sup>1</sup>, D. Schaudien<sup>1</sup>, P. Riese<sup>2</sup>, C. Guzman<sup>2</sup>, R. Stripecke<sup>1</sup>, <sup>1</sup>Hanover, <sup>2</sup>Braunschweig*

\*P 82

**Homeostatic and antigenic support by induced dendritic cells expressing gB amplifies the activation gB-CAR T cells for post-transplant immunotherapy against HCMV**

*H. Olbrich<sup>1</sup>, S. Theobald<sup>1</sup>, M. Mamonkin<sup>2</sup>, R. Stripecke<sup>1</sup>, <sup>1</sup>Hanover, <sup>2</sup>Houston/USA*

P 83

**Illuminating the in vivo tropism of Modified Vaccinia virus Ankara in infected chicken embryos**

*M. Langenmayer, A. Lülff, S. Adam-Neumeier, G. Sutter, A. Volz, Munich*

P 84

**Recombinant Modified Vaccinia virus Ankara vaccines delivering G and F antigens of Nipah Virus**

*S. Veit, A. Freudenstein, A. Volz, G. Sutter, Munich*

P 85

**Development of an Epstein-Barr virus (EBV) epitope quality scoring system for clinical application**

*D. Adhikary<sup>1</sup>, A. Cirac<sup>1</sup>, R. Poirey<sup>2</sup>, H.-J. Delecluse<sup>2</sup>, J. Mautner<sup>1</sup>, U. Behrends<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Heidelberg*

P 86

**Distribution of Ebola virus RNA in organs of vaccinated mice: an in situ hybridization study**

*M. Gellhorn Serra<sup>1</sup>, A. Kupke<sup>1</sup>, E. Dietzel<sup>1</sup>, A. Volz<sup>2</sup>, G. Sutter<sup>2</sup>, S. Becker<sup>1</sup>, <sup>1</sup>Marburg, <sup>2</sup>Munich*

P 87

**Increased expression of the coinhibitors PD-1 and BTLA on CMV-specific T-cells is associated with symptomatic CMV infection in renal transplant patients**

*B. Wilde, J. Reinold, S. Doff, A. Bienholz, C. Struve, H. Guberina, P. Horn, M. Lindemann, O. Witzke, Essen*

\*P 88

**Testing the efficacy of a Measles Virus-derived Zika virus vaccine in a Zika challenge model of pregnant mice**

*C. Nürnberger, B. Bodmer, A. Fiedler, M. Mühlebach, Langen*



## SY IV: MICROBIOME AND INFECTION

P 89

**HLA-B27-restricted CTL-escape mutations increase sensitivity of HIV-1- to Interferon  $\alpha$** *P. Schommers*<sup>1</sup>, *C. Ford*<sup>2</sup>, *A. Hölzemer*<sup>2</sup>, *G. Fätkenheuer*<sup>1</sup>, *M. Altfeld*<sup>2</sup>, <sup>1</sup>Cologne, <sup>2</sup>Hamburg

P 90

**Delay in Adequate Antibiotic Therapy Results in Fatal Disease Outcome in a Mouse Model of CAP***S. Berger*, *C. Gökeri*, *U. Behrendt*, *S.-M. Wienhold*, *J. Lienau*, *N. Suttrop*, *M. Witzernath*, *G. Nouailles*, Berlin

P 91

**C26 - a novel compound inhibiting the expression of type III secretion system 1 of *Salmonella* Typhimurium***I. Grin*<sup>1</sup>, *A. Naini*<sup>2</sup>, *M. Riess*<sup>1</sup>, *M. Brönstrup*<sup>2</sup>, *S. Wagner*<sup>1</sup>, <sup>1</sup>Tübingen, <sup>2</sup>Braunschweig

P 92

**Quality control and assurance of biosamples collected within the frame of the Transplant cohort in DZIF***A. Kühn*<sup>1</sup>, *N. Klopp*<sup>2</sup>, *L. Sandmann*<sup>2</sup>, *F. Schlott*<sup>1</sup>, *S. Engelhardt*<sup>1</sup>, *S. Kukolka*<sup>1</sup>, *H. Nitschko*<sup>1</sup>, *J. Haedicke-Jarboui*<sup>3</sup>, *C. Sommerer*<sup>4</sup>, *N. Metzendorf*<sup>4</sup>, *T. Weis*<sup>4</sup>, *D. Schindler*<sup>1</sup>, *P. Schirmacher*<sup>4</sup>, *C. Gieger*<sup>1</sup>, *G. Anton*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Hanover, <sup>3</sup>Tuebingen, <sup>4</sup>Heidelberg

P 93

**Viral infection dynamics of entomobirnavirus Culex Y virus and the immune response elicited in mosquito cells***M. Leggewie*<sup>1</sup>, *K. Franzke*<sup>2</sup>, *S. Jansen*<sup>1</sup>, *S. Vattipally*<sup>3</sup>, *E. Tannich*<sup>1</sup>, *S. Becker*<sup>4</sup>, *E. Schnettler*<sup>1,3</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Greifswald, <sup>3</sup>Glasgow/United Kingdom, <sup>4</sup>Hanover

P 94

**HIV-1-mediated downmodulation of HLA-C impacts target-cell recognition and antiviral activity of NK cells***C. Körner*<sup>1</sup>, *C. Simoneau*<sup>2</sup>, *P. Schommers*<sup>1,3</sup>, *M. Granoff*<sup>2</sup>, *M. Ziegler*<sup>1</sup>, *A. Hölzemer*<sup>1</sup>, *S. Lunemann*<sup>1</sup>, *J. Chukwukelu*<sup>1</sup>, *B. Corleis*<sup>2</sup>, *V. Naranbhai*<sup>2,4</sup>, *D. Won*<sup>2,5</sup>, *E. Scully*<sup>2,6</sup>, *S. Jost*<sup>2,5</sup>, *F. Kirchhoff*<sup>7</sup>, *M. Carrington*<sup>2,4</sup>, *M. Altfeld*<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Cambridge/USA, <sup>3</sup>Cologne, <sup>4</sup>Frederick/USA, <sup>5</sup>Boston/USA, <sup>6</sup>Baltimore/USA, <sup>7</sup>Ulm

P 95

**Characterisation of the Zika virus induced small RNA response in *Aedes aegypti* cells***M. Varjak*<sup>1</sup>, *C. Donald*<sup>1</sup>, *T. Mottram*<sup>1</sup>, *S. Vattipally*<sup>1</sup>, *A. Merits*<sup>2</sup>, *K. Maringer*<sup>3</sup>, *E. Schnettler*<sup>4</sup>, *A. Kohl*<sup>1</sup>, <sup>1</sup>Glasgow/United Kingdom, <sup>2</sup>Tartu/Estonia, <sup>3</sup>Guildford/United Kingdom, <sup>4</sup>Hamburg

P 96

**Deep rectal swabs for microbiome sampling and analysis in a cohort study of hematological and oncological patients***L. Biehl*<sup>1,2</sup>, *D. Garzett*<sup>3</sup>, *F. Farowski*<sup>1</sup>, *D. Ring*<sup>3</sup>, *M. Koepfel*<sup>3</sup>, *H. Rohde*<sup>2</sup>, *P. Schafhausen*<sup>2</sup>, *B. Stecher*<sup>3</sup>, *M.J. Vehreschild*<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Hamburg, <sup>3</sup>Munich

P 97

**Novel approach to capture and enrich *Mycobacterium tuberculosis* and its DNA from saliva***J. Hansen*<sup>1</sup>, *K. Kolbe*<sup>1,2</sup>, *S. Malm*<sup>1</sup>, *J. Zallett*<sup>1</sup>, *D. Hillemann*<sup>1</sup>, *K.-H. Wiesmüller*<sup>3</sup>, *J. Brandenburg*<sup>1</sup>, *C. Herzmann*<sup>1</sup>, *N. Reiling*<sup>1</sup>, <sup>1</sup>Sülfeld, <sup>2</sup>Bethesda/USA, <sup>3</sup>Tübingen

P 98

**Neoglycopeptides as potential Shiga toxin inhibitors***G. Pohlentz*<sup>1</sup>, *J. Müthing*<sup>1</sup>, *P. Dersch*<sup>2</sup>, *H. Karch*<sup>1</sup>, <sup>1</sup>Münster, <sup>2</sup>Braunschweig

P 99

**Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs***F. Schlott*<sup>1</sup>, *K. Katsirntak*<sup>2</sup>, *D. Steubl*<sup>1</sup>, *W. Puppe*<sup>2</sup>, *D. Hoffmann*<sup>1</sup>, *C. Blume*<sup>2</sup>, *U. Heemann*<sup>1</sup>, *H. Haller*<sup>2</sup>, *L. Renders*<sup>1</sup>, *D. Busch*<sup>1</sup>, *C. Falk*<sup>2</sup>, *M. Neuenhahn*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Hanover

P 100

**Establishment and optimisation of a mouse model for EHEC- and Shiga toxin- mediated pathogenesis***S. Mühlen*, *A. Rolof*, *P. Dersch*, Braunschweig

P 101

**Transcriptional, proteomic and metabolic networks of the Fur and PerR regulated iron and carbon-starvation metabolism of *Clostridium difficile****A.-M. Michel*, *M. Berges*, *M. Neumann-Schaal*, *D. Jahn*, Braunschweig

P 102

**Mode of action of the protein VapA of *Rhodococcus equi* on phagosome membranes***C. Nehls*<sup>1</sup>, *A. Haas*<sup>2</sup>, *J. Bürck*<sup>3</sup>, *K. Komorowski*<sup>1</sup>, *T. Gutsmann*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Bonn, <sup>3</sup>Karlsruhe

P 103

**A Comparative Study on Techniques for the Determination of Lipid Bilayer Permeabilization***L. Paulowski*<sup>1</sup>, *N. Gebauer*<sup>1</sup>, *J. Wernecke*<sup>1,2</sup>, *B. Cornell*<sup>3</sup>, *T. Gutsmann*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Hamburg, <sup>3</sup>Sydney/Australia

P 104

**High malaria positivity as well as high prevalence of infections due to gram-positive bacteria and arthropod-borne infections in febrile outpatients attending a rural hospital in Southwestern Tanzania***N. Heinrich*<sup>1</sup>, *J. Dreisbach*<sup>1</sup>, *O. Geisenberger*<sup>1</sup>, *B. Flach*<sup>1</sup>, *C. Mangu*<sup>2</sup>, *L. Sud*<sup>2</sup>, *L. Maboko*<sup>2</sup>, *H. Schimanowski-Thomson*<sup>3</sup>, *C. Mwansongela*<sup>2</sup>, *G. Dobler*<sup>1</sup>, *M. Hölscher*<sup>1</sup>, *C. Scheiber*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Mbeya/Tanzania, <sup>3</sup>Matema/Tanzania

P 105

**Leptin signaling regulates macrophage mediated inflammatory responses against *Salmonella* Typhimurium through mTORC2***J. Fischer*, *S. Gutiérrez*, *R. Ganesan*, *M. Wolke*, *J. Cassens*, *J. Brüning*, *P. Hartmann*, *G. Plum*, *N. Robinson*, Cologne

**P 106****Evaluation of Data Accuracy of the Surveillance Outbreak Response Management and Analysis System (SORMAS)**

*S. Toikkanen*<sup>1</sup>, *S. Glöckner*<sup>1</sup>, *A. Olawunmi*<sup>2</sup>, *C. Ameh*<sup>2</sup>, *J. Benzler*<sup>3</sup>, *G. Kirchner*<sup>3</sup>, *G. Poggensee*<sup>2</sup>, *D. Tom-Aba*<sup>1</sup>, *G. Krause*<sup>1</sup>, <sup>1</sup>Braunschweig, <sup>2</sup>Abuja/Nigeria, <sup>3</sup>Berlin

**SY V: RESISTANCE IN NOSOCOMIAL INFECTIONS****\*P 107****Implementierung von Antibiotic stewardship an einem Haus der Grund- und Regelversorgung: Konzept und Ergebnisse**

*M. Bonsignore*<sup>1</sup>, *E. Balamitsa*<sup>1</sup>, *C. Nobis*<sup>1</sup>, *C. Geffers*<sup>2</sup>, *I. Nachtigal*<sup>2</sup>, <sup>1</sup>Gelsenkirchen, <sup>2</sup>Berlin

**P 108****Antibiotic Stewardship auf einer neurologischen Intensivstation an einem Universitätsklinikum**

*C. Blei*, *A. Dudakova*, *H. Eiffert*, *S. Scheithauer*, *U. Groß*, *J. Liman*, *K. Hein*, *M. Schulze*, Göttingen

**P 109****Studies on the Resistance Mechanism of the Novel Topoisomerase Inhibitor Cystobactamid**

*K. Cirniski*<sup>1,2</sup>, *J. Herrmann*<sup>1,2</sup>, *G. Testolin*<sup>2,3</sup>, *S. Hütte*<sup>2,3</sup>, *N. Zaboranyi*<sup>1,2</sup>, *M. Stadler*<sup>2,3</sup>, *M. Brönstrup*<sup>2,3</sup>, *R. Müller*<sup>1,2</sup>, <sup>1</sup>Saarbrücken, <sup>2</sup>Hanover, <sup>3</sup>Braunschweig

**P 110****Mechanism-of-Action of the Cyclic Depsipeptide Antibiotic Telomycin**

*F. Hennessen*<sup>1,2</sup>, *J. Herrmann*<sup>1,2</sup>, *A. Abou Fayad*<sup>1,2</sup>, *K. Cirniski*<sup>1,2</sup>, *H.-P. Prochnow*<sup>2,3</sup>, *A. Bauer*<sup>4</sup>, *J. Pippe*<sup>2,3</sup>, *W. Blankenfeldt*<sup>2,3</sup>, *M. Brönstrup*<sup>2,3</sup>, *R. Müller*<sup>2,3</sup>, <sup>1</sup>Saarbrücken, <sup>2</sup>Hanover, <sup>3</sup>Braunschweig, <sup>4</sup>Frankfurt am Main

**P 111****Multilayer network modelling of hospital infections**

*A. Jarynowski*<sup>1,2</sup>, *A. Grabowski*<sup>3</sup>, *D. Marchewka*<sup>2</sup>, <sup>1</sup>Wroclaw/Poland, <sup>2</sup>Krakow/Poland, <sup>3</sup>Warsaw/Poland

**\*P 112****Fluoroquinolone non-susceptibility in 3rd generation cephalosporin resistant Enterobacteriaceae in German university hospitals**

*A. Rohde*<sup>1</sup>, *J. Zweigner*<sup>2</sup>, *M. Wiese-Posselt*<sup>1</sup>, *H. Seifert*<sup>2</sup>, *P. Gastmeier*<sup>1</sup>, *W. Kern*<sup>3</sup>, *S. Athos*<sup>1,2,3,4,5,6</sup>, <sup>1</sup>Berlin, <sup>2</sup>Cologne, <sup>3</sup>Freiburg, <sup>4</sup>Lübeck, <sup>5</sup>Tübingen, <sup>6</sup>Munich

**\*P 113****Early bacterial colonization and antibiotic resistance gene acquisition in newborns**

*H. Slevogt*<sup>1</sup>, *T. Klassert*<sup>1</sup>, *S. Kankel*<sup>1</sup>, *M. Stock*<sup>1</sup>, *C. Zuberia-Barrera*<sup>1</sup>, *N. Doehring*<sup>2</sup>, *D. Fischer*<sup>2</sup>, <sup>1</sup>Jena, <sup>2</sup>Frankfurt/Main

**P 114****Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2009 to 2016, data from the German Antibiotic Resistance Surveillance System (ARS)**

*U. Koppe*, *A. von Laer*, *I. Noll*, *M. Feig*, *M. Abu Sin*, *T. Eckmanns*, Berlin

**P 115****Co-resistance of Carbapenem non-susceptible Klebsiella pneumoniae to other classes of antibiotics in hospitals from 2009 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)**

*U. Koppe*, *A. von Laer*, *I. Noll*, *M. Feig*, *M. Abu Sin*, *T. Eckmanns*, Berlin

**P 116****Inzidenz und Risikofaktoren für Blutstrominfektionen bei Intensivpatienten mit großflächigen Verbrennungen: eine monozentrische retrospektive Kohortenstudie**

*A. Fochtmann-Frana*<sup>1</sup>, *C. Freystätter*<sup>1</sup>, *V. Vorstandlechner*<sup>1</sup>, *A. Barth*<sup>1</sup>, *M. Bolliger*<sup>1</sup>, *E. Presterl*<sup>1</sup>, *G. Ibra*<sup>1</sup>, *G. Muschitz*<sup>1</sup>, *M. Mittlböck*<sup>1</sup>, *A. Makrithis*<sup>1</sup>, *T. Rath*<sup>1</sup>, *C. Radtke*<sup>1</sup>, *C. Forstner*<sup>1,2</sup>, <sup>1</sup>Vienna/Austria, <sup>2</sup>Jena

**\*P 117****Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiological eradication despite clinical improvement: a non-comparative, prospective observational study**

*C. Forstner*<sup>1,2</sup>, *A. Kwetkat*<sup>1</sup>, *O. Makarewicz*<sup>1</sup>, *A. Hartung*<sup>1</sup>, *W. Pster*<sup>1</sup>, *H. Stefan*<sup>1</sup>, *N. Harrison*<sup>2</sup>, *U. Schumacher*<sup>1</sup>, *M. Pletz*<sup>1</sup>, <sup>1</sup>Jena, <sup>2</sup>Vienna/Austria

**\*P 118****Stellen die zunehmenden Nachweise von MRSA CC398 als Hospitalkeim bei Pferden ein Risiko für deren Kontaktpersonen dar?**

*C. Cuny*<sup>1</sup>, *W. Witte*<sup>1</sup>, *M. Abdelbary*<sup>2</sup>, *F. Layer*<sup>1</sup>, *G. Werner*<sup>1</sup>, <sup>1</sup>Wernigerode, <sup>2</sup>Lausanne/Switzerland

**P 119****Two-tier approach combining molecular and culture-based techniques for optimized detection of vancomycin-resistant enterococci**

*A. Both*, *G. Franke*, *N. Miwald*, *M. Christner*, *M. Lütgehetmann*, *E.-M. Klupp*, *C. Belmar Campos*, *H. Büttner*, *M. Aepfelbacher*, *H. Rohde*, Hamburg

**P 120****Limiting spread of vancomycin-resistant enterococci (VRE) by applying probiotics to patients receiving antibiotics**

*S. Borgmann*<sup>1</sup>, *B. RieB*<sup>1</sup>, *B. Jürgens*<sup>1</sup>, *R. Siegmund*<sup>1</sup>, *G. Werner*<sup>2</sup>, *I. Klare*<sup>2</sup>, <sup>1</sup>Ingolstadt, <sup>2</sup>Wernigerode

**\*P 121****Electronic medication systems simplify antimicrobial prescription review by clinical pharmacists and facilitate complex antimicrobial stewardship interventions**

*C. Sommer*, *F. Olearo*, *J. Jochum*, *H. Hilgarth*, *J. Katchanov*, *C. Langebrake*, *M. Baehr*, *A.W. Lohse*, *F. Maurer*, Hamburg

**P 122****Preclinical development of HY-133, a recombinant phage lysin for rapid decolonization of Staphylococcus aureus from nasal habitats**

*E. Idelevich*<sup>1</sup>, *S. Molinaro*<sup>2</sup>, *S. Eisele*<sup>3</sup>, *B. Krismer*<sup>4</sup>, *C. Weidenmaier*<sup>4</sup>, *L. Heitmann*<sup>5</sup>, *G. Winter*<sup>3</sup>, *T. Hesterkamp*<sup>5</sup>, *W. Mutter*<sup>2</sup>, *K. Becker*<sup>1</sup>, *A. Peschel*<sup>4</sup>, <sup>1</sup>Münster, <sup>2</sup>Bernried, <sup>3</sup>Munich, <sup>4</sup>Tübingen, <sup>5</sup>Braunschweig

## ★P 123

**Diversity of porin loss and  $\beta$ -lactamase presence in carbapenem resistant *Klebsiella pneumoniae***  
*L. Biniössek*<sup>1</sup>, *S. Gerson*<sup>1</sup>, *K. Xanthopoulou*<sup>1</sup>, *J. Ertel*<sup>1</sup>, *M. Kaase*<sup>2</sup>, *H. Seifert*<sup>1</sup>, *P. Higgins*<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Bochum

## ★P 124

**Bloodstream Infection due to Multidrug-Resistant Organisms – Multicenter Study on Determinants of Clinical Outcomes (BLOOMY.COM)**  
*S. Eisenbeis*<sup>1</sup>, *A. Mischnik*<sup>2</sup>, *M. Buhl*<sup>1</sup>, *S. Peter*<sup>1</sup>, *J. Falgenhauer*<sup>3</sup>, *N. Kaeding*<sup>4,5</sup>, *A. Rohde*<sup>6</sup>, *M. Vehreschild*<sup>7</sup>, *T. Chakraborty*<sup>3</sup>, *P. Gastmeier*<sup>8</sup>, *J. Rupp*<sup>4,5</sup>, *H. Seifert*<sup>7,8</sup>, *W. Kern*<sup>2</sup>, *E. Tacconelli*<sup>1</sup>, *F. Hölzl*<sup>1</sup>, <sup>1</sup>Tübingen, <sup>2</sup>Freiburg, <sup>3</sup>Giessen, <sup>4</sup>Lübeck, <sup>5</sup>Hamburg-Lübeck-Borstel, <sup>6</sup>Berlin, <sup>7</sup>Cologne, <sup>8</sup>Bonn

## ★P 125

**Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis**  
*D. Baur*, *B.P. Gladstone*, *F. Burkert*, *E. Carrara*, *F. Foschi*, *S. Döbele*, *E. Tacconelli*, Tübingen

## ★P 126

**Novel clone of *Serratia marcescens* associated with neonatal outbreaks in Germany: A novel subspecies?**  
*S. Doijad*<sup>1</sup>, *Y. Yao*<sup>1</sup>, *L. Falgenhauer*<sup>1</sup>, *M. Fritzenwanker*<sup>1</sup>, *H. Ghosh*<sup>1</sup>, *K. Gwozdziński*<sup>1</sup>, *R. Hilker*<sup>1</sup>, *O. Schwengers*<sup>1</sup>, *B. Abt*<sup>2</sup>, *B. Bunk*<sup>2</sup>, *S. Reuter*<sup>3</sup>, *C. Imirzalioglu*<sup>1</sup>, *P. Gastmeier*<sup>4</sup>, *A. Kola*<sup>4</sup>, *A. Goesmann*<sup>1</sup>, *J. Overmann*<sup>2</sup>, *H. Grundmann*<sup>3</sup>, *T. Chakraborty*<sup>1</sup>, <sup>1</sup>Gießen, <sup>2</sup>Braunschweig, <sup>3</sup>Freiburg, <sup>4</sup>Berlin

## SY VI: DRUG RESISTANCE AND CONTROL OF TUBERCULOSIS AND PARASITIC INFECTIONS

## P 127

**Trypanosoma cruzi escapes elimination through the induction of co-inhibitory receptors on T cells**  
*R. Grote-Gálvez*, *T. Jacobs*, Hamburg

## P 128

**Inhibition of neutrophil myeloperoxidase controls M. tuberculosis induced-necrosis and growth after phagocytosis by macrophages**  
*T. Dallenga*<sup>1</sup>, *U. Repnik*<sup>2</sup>, *R. Reimer*<sup>1,3</sup>, *G. Griffiths*<sup>2</sup>, *U. Schaible*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Oslo/Norway, <sup>3</sup>Hamburg

## P 129

**TB SEQUEL: Pathogenesis and risk factors of long-term pulmonary sequelae defining the individual outcome and public health impact of TB disease**  
*A. Rachow*<sup>1</sup>, *N. Bhatt*<sup>2</sup>, *B. Kampmann*<sup>3</sup>, *N. Ntinginya*<sup>4</sup>, *I. Sanne*<sup>5</sup>, *K. Lonnroth*<sup>6</sup>, *S. Niemann*<sup>7</sup>, *R. Wallis*<sup>8</sup>, *M. Hoelscher*<sup>1</sup>, *G. Churchyard*<sup>9</sup>, <sup>1</sup>Munich, <sup>2</sup>Maputo/Mozambique, <sup>3</sup>Banjul/Gambia, <sup>4</sup>Mbeya/Tanzania, <sup>5</sup>Johannesburg/South Africa, <sup>6</sup>Geneva/Switzerland, <sup>7</sup>Borstel

## P 130

**Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells**  
*I. Kroidl*<sup>1</sup>, *M. Chachage*<sup>2</sup>, *J. Mnka*<sup>2</sup>, *A. Nsojo*<sup>2</sup>, *M. Berninghoff*<sup>1</sup>, *L. Maganga*<sup>2</sup>, *J. Verweij*<sup>3</sup>, *A. Hoerauf*<sup>1</sup>, *N. Ntinginya*<sup>2</sup>, *P. Clowes*<sup>2</sup>, *M. Hoelscher*<sup>1</sup>, *E. Saathoff*<sup>1</sup>, *C. Geldmacher*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Mbeya/Tanzania, <sup>3</sup>Tilburg/Netherlands, <sup>4</sup>Bonn

## P 131

**Concurrent helminth infection interferes with vaccine-induced protection against influenza virus infection**  
*W. Hartmann*, *N. Kruse*, *G. Gabriel*, *M.-L. Brunn*, *M. Breloer*, Hamburg

## P 132

**Distribution of the Usutu virus and its impact on bird populations in Germany**  
*R. Lühken*<sup>1</sup>, *S. Thomas*<sup>2</sup>, *H. Jöst*<sup>1</sup>, *N. Tjaden*<sup>2</sup>, *U. Ziegler*<sup>3</sup>, *M. Groschup*<sup>3</sup>, *C. Beierkuhnlein*<sup>2</sup>, *J. Schmidt-Chanasit*<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Bayreuth, <sup>3</sup>Riems

## P 133

**Preclinical development of the novel antibiotic Corallopyronin A for filariasis and bacterial infections**  
*A. Hoerauf*<sup>1</sup>, *A. Schiefer*<sup>1</sup>, *A. Krome*<sup>1</sup>, *S. Bouhired*<sup>1</sup>, *S. Kehraus*<sup>1</sup>, *K. Wagner*<sup>1</sup>, *M. Stadler*<sup>2</sup>, *R. Jansen*<sup>2</sup>, *M. Roth*<sup>3</sup>, *R. Müller*<sup>4</sup>, *T. Schäberle*<sup>1</sup>, *G. König*<sup>1</sup>, *K. Pfarr*<sup>1</sup>, <sup>1</sup>Bonn, <sup>2</sup>Braunschweig, <sup>3</sup>Jena, <sup>4</sup>Saarbrücken

## P 134

**Towards a structural and functional model of the PfEMP1 mediated host-pathogen interactions for the development of novel treatment options against malaria**  
*L. Ehnold*, *N. Mohr*, *F. Geisinger*, *S. Ofori*, *L. Roth*, *I. Bruchhaus*, *S. Witt*, Hamburg

## P 135

**Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible tuberculosis: a systematic review and meta-analysis**  
*B. Lange*<sup>1</sup>, *C. Kodama*<sup>2,3</sup>, *I. Olaru*<sup>4</sup>, *P. Khan*<sup>2</sup>, *M. Lipman*<sup>2</sup>, *J. Seddon*<sup>2</sup>, *D. Sloan*<sup>5</sup>, *L. Grandjean*<sup>2</sup>, *R. Ferrand*<sup>2</sup>, *K. Kranzer*<sup>2,4</sup>, <sup>1</sup>Freiburg, <sup>2</sup>London/United Kingdom, <sup>3</sup>Geneva/Switzerland, <sup>4</sup>Borstel, <sup>5</sup>St Andrews/United Kingdom

## ★P 136

**Novel TB immune-diagnostic test (TAM-TB) allows for treatment monitoring in a rare case of tuberculous coxitis**  
*M. Ahmed*, *I. Dubinsky*, *K. Held*, *C. Geldmacher*, *U. von Both*, Munich

## ★P 137

**Ending the diagnostic dilemma in TB: proposing better study designs to validate new diagnostics**  
*L. Olbrich*<sup>1</sup>, *U. von Both*<sup>1</sup>, *U. Behrends*<sup>1</sup>, *S. Niemann*<sup>2</sup>, *C. Geldmacher*<sup>1</sup>, *K. Avsar*<sup>3</sup>, *M. Seilmaier*<sup>1</sup>, *M. Steinhauser*<sup>1</sup>, *H. Hoffmann*<sup>3</sup>, *M. Hoelscher*<sup>1</sup>, *N. Heinrich*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Borstel, <sup>3</sup>Gauting

## P 138

**Laboratory implementation of Next Generation Sequencing for medium and high throughput whole genome analysis of clinical M. tuberculosis complex strains**  
*V. Mohr*, *J. Zallet*, *T. Ubben*, *C. Hahn*, *T. Struve-Sonnenschein*, *A. Lüdemann*, *V. Schleusener*, *K. Kranzer*, *C. Utpatel*, *T. Kohl*, *S. Niemann*, Borstel

## P 139

**Analytical Quantification Techniques for Corallopyronin A - suitable for different stages of its development**  
*A. Krome*, *S. Bouhired*, *S. Kehraus*, *A. Schiefer*, *K. Pfarr*, *A. Hoerauf*, *K. Wagner*, *G. König*, Bonn



**P 140****Human iPSC-derived macrophages as a tool to study the susceptibility to mycobacterial infections**

*K. Haake*<sup>1</sup>, *J. Lam*<sup>1</sup>, *A.-L. Neehus*<sup>1</sup>, *M. Ackermann*<sup>1</sup>, *S. Merkert*<sup>1</sup>, *M. Schubert*<sup>1</sup>, *C. Happle*<sup>1</sup>, *U. Martin*<sup>1</sup>, *U. Baumann*<sup>1</sup>, *A. Schambach*<sup>1</sup>, *J. Bustamante*<sup>2</sup>, *J. Roesler*<sup>3</sup>, *N. Lachmann*<sup>1</sup>, <sup>1</sup>Hanover, <sup>2</sup>Paris/France, <sup>3</sup>Dresden

**P 141****The treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) patients in Gabon: Implementation of the short course regimen (9 months), interim results**

*J. Edoa*<sup>1,2</sup>, *U. Ateba-Ngoa*<sup>1,2</sup>, *M. Massinga-Loembe*<sup>1,2</sup>, *D. Madiou*<sup>1</sup>, *R. Adegbite*<sup>1,2</sup>, *S. Gould*<sup>1,2</sup>, *G. Rossatanga*<sup>1</sup>, *A. Mfoumbi*<sup>1,2</sup>, *C. Mevyann*<sup>1,2</sup>, *J. Mahoumbou*<sup>3</sup>, *A. Alabi*<sup>1,2</sup>, *B. Lell*<sup>1,2</sup>, *P. Kreamsner*<sup>1,2</sup>, *A. Adegnika*<sup>1,2</sup>, *M. Grobusch*<sup>1,2,4</sup>, <sup>1</sup>Lambaréné/Gabon, <sup>2</sup>Tübingen, <sup>3</sup>Libreville/Gabon, <sup>4</sup>Amsterdam/Netherlands

**P 142****Usage of RNAi-based trigger gene silencing to identify pathogenicity factors of *Entamoeba histolytica* involved in amoebic liver abscess formation**

*S. Lender*, *J. Matthiesen*, *H. Fehling*, *M. Meyer*, *H. Lotter*, *I. Bruchhaus*, Hamburg

**P 143****Interaction Between Host Defence Peptides and Mycobacteria**

*C. Nehls*<sup>1</sup>, *L. Paulowski*<sup>1</sup>, *S. Willcocks*<sup>2</sup>, *N. Reiling*<sup>1</sup>, *U. Schaible*<sup>1</sup>, *T. Gutschmann*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>London/United Kingdom

**\*P 144****Corticosteroids potently abrogate RIPK1-independent necrosis of Mycobacterium tuberculosis – implications for host-directed therapies**

*J. Gräß*<sup>1</sup>, *E. van Gumpel*<sup>1</sup>, *S. Winter*<sup>1</sup>, *A. Cato*<sup>2</sup>, *C. Hölscher*<sup>3</sup>, *J. Rybniker*<sup>1</sup>, <sup>1</sup>Cologne, <sup>2</sup>Karlsruhe, <sup>3</sup>Borstel

**\*P 145****Neutrophil proteins as potential signatures for point-of-care diagnostic and putative targets for host-directed-therapy in tuberculosis**

*C. Leschczyk*<sup>1</sup>, *T. Dallenga*<sup>1</sup>, *K. Laxmikanth*<sup>2</sup>, *V. Sparr*<sup>1</sup>, *B. Karlsdorf*<sup>1</sup>, *A. Sickmann*<sup>2</sup>, *U. Schaible*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Dortmund

**P 146****Numerical chest X-ray score can be used as a predictive factor in treatment of tuberculosis**

*S. Konsten*<sup>1</sup>, *P. Phillips*<sup>2</sup>, *N. Ntinginya*<sup>3</sup>, *L. Minja*<sup>4</sup>, *K. Reither*<sup>5</sup>, *G. Kibiki*<sup>6</sup>, *I. Sanne*<sup>7</sup>, *K. Mellet*<sup>7</sup>, *A. Diacon*<sup>8</sup>, *R. Dawson*<sup>9</sup>, *G. Churchyard*<sup>7</sup>, *A. Nunn*<sup>2</sup>, *A. Colbers*<sup>10</sup>, *A. Mekota*<sup>1</sup>, *S. Gillespie*<sup>11</sup>, *M. Boeree*<sup>10</sup>, *R. Aarnoutse*<sup>10</sup>, *M. Hoelscher*<sup>1</sup>, *N. Heinrich*<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>London/United Kingdom, <sup>3</sup>Mbeya/Tanzania, <sup>4</sup>Bagamoyo/Tanzania, <sup>5</sup>Basel/Switzerland, <sup>6</sup>Moshi/Tanzania, <sup>7</sup>Johannesburg/South Africa, <sup>8</sup>Tygerberg/South Africa, <sup>9</sup>Cape Town/South Africa, <sup>10</sup>Nijmegen/Netherlands, <sup>11</sup>St Andrews/United Kingdom

**P 147****Impact of naturally acquired immunity to *P. falciparum* on var gene expression in controlled human malaria infections**

*A. Bachmann*<sup>1</sup>, *E. Bruske*<sup>2</sup>, *R. Krumkamp*<sup>1</sup>, *L. Turner*<sup>3</sup>, *J.S. Wichers*<sup>1</sup>, *M. Petter*<sup>1</sup>, *B.K.L. Sim*<sup>5</sup>, *S.L. Hoffman*<sup>5</sup>, *P. Kreamsner*<sup>2</sup>, *M. Frank*<sup>2</sup>, *B. Lell*<sup>6</sup>, *T. Lavstsen*<sup>3</sup>, *B. Mordmüller*<sup>2</sup>, *E. Tannich*<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Tübingen, <sup>3</sup>Copenhagen/Denmark, <sup>4</sup>Erlangen, <sup>5</sup>Rockville/USA, <sup>6</sup>Lambaréné/Gabon

**\*P 148****Evaluation of BTZ043 in the standard mouse model of tuberculosis infection and a novel model reflecting human pathology**

*K. Walter*<sup>1</sup>, *N. Heinrich*<sup>2</sup>, *J. Dreisbach*<sup>2</sup>, *J. Kokesch-Himmelreich*<sup>3</sup>, *A. Römpf*<sup>3</sup>, *M. Hölscher*<sup>2</sup>, *C. Hölscher*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Munich, <sup>3</sup>Bayreuth

**P 149****The IL-23/IL-17-axis negatively regulates the IL-13- and Ly6C<sup>lo</sup> monocyte-dependent tissue regeneration during hepatic amebiasis**

*J. Noll*<sup>1</sup>, *E. Helk*<sup>1</sup>, *H. Fehling*<sup>1</sup>, *H. Bernin*<sup>1</sup>, *T. Jacobs*<sup>1</sup>, *T. Ernst*<sup>1</sup>, *H. Ittrich*<sup>1</sup>, *C. Hölscher*<sup>2</sup>, *H. Lotter*<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Sülfeld

**\*P 150****The role of intracellular pH for chloroquine action and resistance in *Plasmodium falciparum***

*J. Wunderlich*<sup>1,2</sup>, <sup>1</sup>Berlin, <sup>2</sup>Montreal/Canada

**\*P 151****Identification of *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) molecules involved in the interaction with various human endothelial receptors**

*L. Roth*, *N. Metwally*, *A.-K. Tilly*, *M. Dörpinghaus*, *P. Lubiana*, *S. Witt*, *E. Tannich*, *I. Bruchhaus*, Hamburg

**P 152****Changes in the transcriptome of human brain endothelial cells (HBECs) due to a *Plasmodium falciparum* malaria infection**

*M. Dörpinghaus*, *F. Fürstenwerth*, *L. Roth*, *N. Galal Metwally*, *P. Lubiana*, *E. Tannich*, *T. Jacobs*, *I. Bruchhaus*, Hamburg

**\*P 153****Development of a Therapeutic Drug Monitoring platform for personalized treatment of patients with M/XDR-TB**

*H. Karakose*<sup>1</sup>, *N. Köhler*<sup>1</sup>, *C. Lange*<sup>1,2,3,4</sup>, *P. Sanchez-Carballo*<sup>1</sup>, *D. Schwudke*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Windhoek/Namibia, <sup>3</sup>Lübeck, <sup>4</sup>Stockholm/Sweden

**\*P 154****A longitudinal molecular epidemiological study of tuberculosis in Hanover**

*P. Beckert*<sup>1</sup>, *M. Yilmaz*<sup>2</sup>, *A. Hanke-Lensing*<sup>2</sup>, *M. Bliemeister*<sup>2</sup>, *S. Gerdes*<sup>1,2</sup>, *S. Niemann*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Hanover

**P 155****A five years molecular epidemiological study of tuberculosis in Lambaréné, Gabon - Investigation of outbreak strains.**

*P. Beckert*<sup>1</sup>, *E. Bruske*<sup>2</sup>, *S. Bélard*<sup>2,3,4,5</sup>, *A. Traoré*<sup>3,6</sup>, *D. Kombila*<sup>3</sup>, *H. Lay*<sup>2</sup>, *J. Frick*<sup>2</sup>, *S. Janssen*<sup>3,4,7</sup>, *T. Kohl*<sup>1</sup>, *B. Lell*<sup>2,3</sup>, *P. Kreamsner*<sup>2,3</sup>, *M. Frank*<sup>2</sup>, *A. Alabi*<sup>3</sup>, *M. Grobusch*<sup>2,4,7</sup>, *S. Niemann*<sup>1</sup>, <sup>1</sup>Borstel, <sup>2</sup>Tuebingen, <sup>3</sup>Lambaréné/Gabon, <sup>4</sup>Amsterdam/Netherlands, <sup>5</sup>Berlin, <sup>6</sup>Thohoyandou/South Africa, <sup>7</sup>Cape Town/South Africa

**P 156****Profiling the expression dynamics of virulence-associated genes in clinical *Plasmodium falciparum* isolates**

*J. Wichers*<sup>1</sup>, *J. Scholz*<sup>1</sup>, *H. von Thien*<sup>1</sup>, *S. Lorenzen*<sup>1</sup>, *M. Petter*<sup>2</sup>, *M. Duffy*<sup>3</sup>, *E. Tannich*<sup>1</sup>, *A. Bachmann*<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Erlangen, <sup>3</sup>Melbourne/Australia

**P 157****Development of a high resolution MALDI imaging method for the characterization of Mycobacterium tuberculosis (Mtb) pathology**

*J. Kokesch-Himmelreich<sup>1</sup>, A. Fatangare<sup>1</sup>, K. Walter<sup>2</sup>, J. Dreisbach<sup>3</sup>, N. Heinrich<sup>3</sup>, M. Hölscher<sup>3</sup>, C. Hölscher<sup>2</sup>, A. Römpf<sup>1</sup>, <sup>1</sup>Kulmbach, <sup>2</sup>Borstel, <sup>3</sup>Munich*

**P 158****Autoantibodies as biomarkers to diagnose children with P.falciparum malaria**

*N. Struck<sup>1</sup>, R. Krumkamp<sup>1</sup>, T. Jacobs<sup>1</sup>, D. Winter<sup>1</sup>, M. Zimmermann<sup>1</sup>, D. Eibach<sup>1</sup>, L. Reigl<sup>1</sup>, E. Owusu-Dabo<sup>2</sup>, J. May<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Kumasi/Ghana*

**P 159****Identification and characterization of parasite phospholipases involved in Plasmodium falciparum egress from red blood cells**

*P.-C. Burda, F. Nkrumah, H. Matthiesen, T.-W. Gilberger, Hamburg*

**P 160****The dry season reservoir of P. falciparum infection and a possible sensing mechanism**

*C. Andrade<sup>1</sup>, S. Doumbo<sup>2</sup>, L. Djibo<sup>2</sup>, C. Anderson<sup>1</sup>, S. Li<sup>3</sup>, D. Doumtabe<sup>2</sup>, C. Martens<sup>4</sup>, S. Porcella<sup>4</sup>, O. K. Doumbo<sup>2</sup>, K. Kayentao<sup>2</sup>, A. Ongoiba<sup>2</sup>, B. Traore<sup>2</sup>, P. Crompton<sup>3</sup>, S. Portugal<sup>1</sup>, <sup>1</sup>Heidelberg, <sup>2</sup>Bamako/Mali, <sup>3</sup>Rockville, Maryland/USA, <sup>4</sup>Hamilton, Montana/USA*

**P 161****Inflammatory marker response during the dry season reservoir of P. falciparum infection**

*C. Anderson<sup>1</sup>, S. Doumbo<sup>2</sup>, L. Djibo<sup>2</sup>, C. Andrade<sup>1</sup>, S. Li<sup>3</sup>, D. Doumtabe<sup>2</sup>, O. Doumbo<sup>2</sup>, K. Kayentao<sup>2</sup>, A. Ongoiba<sup>2</sup>, B. Traore<sup>2</sup>, P. Crompton<sup>3</sup>, S. Portugal<sup>1</sup>, <sup>1</sup>Heidelberg, <sup>2</sup>Bamako/Mali, <sup>3</sup>Maryland/USA*

**P 162****Viszerale Leishmaniose bei einem HIV+-Patienten**

*S. Jansen, H. Guberina, S. Doff, D. Föhring, S. Esser, O. Witzke, Essen*

**P 163****The molecular nature of the potent T-cell antigen: the molecule of the old tuberculin skin test and its molecular promiscuity.**

*C. Magana, C. Kallenberg, C. Huebner, Y.H. Song, Lübeck*

**P 164****Treatment of lymphatic filariasis and onchocerciasis – current and new therapeutic approaches**

*U. Klarmann-Schulz<sup>1</sup>, L. Batsa-Debrah<sup>2</sup>, K. Pfarr<sup>1</sup>, J. Osei-Mensah<sup>2</sup>, A. Schiefer<sup>1</sup>, A. Debrah<sup>2</sup>, A. Hoerauf<sup>1</sup>, <sup>1</sup>Bonn, <sup>2</sup>Kumasi/Ghana*

**P 165****Human genetic variant affecting calcium pump expression in red blood cells impedes parasite growth and protects from severe malaria**

*C. Strauss, K. Schuld, T. Thye, G. Ruge, J. Sievertsen, B. Muntau, R. Horstmann, C. Timmann, Hamburg*

## VARIA (KLINISCHE INFEKTOLOGIE)

**\*P 166****Resistenzsituation bei ambulant erworbener unkomplizierter Harnwegsinfektion in Deutschland 2015 (SARHA-Studie)**

*A. Klingenberg<sup>1</sup>, N. Willrich<sup>1</sup>, M. Feig<sup>1</sup>, I. Noll<sup>1</sup>, K. Oberdorfer<sup>2</sup>, A. Krenz-Weinreich<sup>3</sup>, D. Emrich<sup>1</sup>, E. Zill<sup>1</sup>, W. Kalka-Moll<sup>4</sup>, T. Eckmanns<sup>1</sup>, <sup>1</sup>Berlin, <sup>2</sup>Heidelberg, <sup>3</sup>Plön, <sup>4</sup>Mönchengladbach*

**P 167****Transient suppression of pro-inflammatory T-cell subsets during experimental endotoxemia in healthy men**

*A. Brinkhoff, A. Sieberichs, H. Engler, S. Doff, S. Benson, J. Korth, M. Schedlowski, A. Kribben, B. Wilde, O. Witzke, Essen*

**P 168****Einfluss von Diabetes mellitus (Typ 2) auf Inzidenz und Verlauf einer spontan bakteriellen Peritonitis bei Patienten mit Leberzirrhose und Aszites**

*T. Tergast<sup>1</sup>, H. Laser<sup>1</sup>, M. Manns<sup>1,2</sup>, M. Cornberg<sup>1,2</sup>, B. Maasoumy<sup>1,2</sup>, <sup>1</sup>Hanover, <sup>2</sup>Braunschweig*

**P 169****Dosisabhängige Effekte von Protonenpumpeninhibitoren auf den Verlauf einer spontan bakteriellen Peritonitis**

*T. Tergast<sup>1</sup>, H. Laser<sup>1</sup>, A. Wranke<sup>1</sup>, M. Manns<sup>1,2</sup>, M. Cornberg<sup>1,2</sup>, B. Maasoumy<sup>1,2</sup>, <sup>1</sup>Hanover, <sup>2</sup>Braunschweig*

**\*P 170****Implementation of a Standard Diet Regimen for Neutropenic High Risk Cancer Patients: Effects on Incidence of Infections, Foodborne Diseases, and Outcome**

*C. Jakob<sup>1</sup>, A. Löhnert<sup>1,2</sup>, M. Stecher<sup>1,2</sup>, O. Cornely<sup>1</sup>, J. Vehreschild<sup>1,2</sup>, <sup>1</sup>Cologne, <sup>2</sup>Bonn*

**P 171****Causes of severe febrile illness in hospitalized children, Nouna Burkina Faso**

*C. Dah<sup>1</sup>, M. Seynou<sup>1</sup>, S. Gies<sup>2</sup>, J. Kompenhans<sup>2</sup>, R. Sorgho<sup>2</sup>, A. Sié<sup>1</sup>, B. Coulibaly<sup>1</sup>, R. Sauerborn<sup>2</sup>, A. Soares<sup>2</sup>, <sup>1</sup>Nouna/Burkina Faso, <sup>2</sup>Heidelberg*

**\*P 172****Experimental transmission of Zika virus by mosquitoes from Central Europe\***

*A. Heitmann<sup>1</sup>, S. Jansen<sup>1</sup>, R. Lühken<sup>1</sup>, M. Leggewie<sup>1</sup>, M. Badusche<sup>1</sup>, B. Pluskota<sup>2</sup>, N. Becker<sup>2,3</sup>, O. Vapalahti<sup>4</sup>, J. Schmidt-Chanasit<sup>1</sup>, E. Tannich<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Speyer, <sup>3</sup>Heidelberg, <sup>4</sup>Helsinki/Finland*

**P 173****Anti-metabolic effects of first-choice antimicrobials against C. trachomatis**

*N. Schmidt, M. Wanker, N. Käding, K. Shima, J. Rupp, Lübeck*

**P 174****"Gut vs butt": Comparative analysis of the HIV reservoir size in distinct CD4+ T cell subsets in the terminal ileum, rectum, and peripheral blood of HIV-1 positive patients**

*C. Horn, M. Augustin, J. Rybniker, D. Nierhoff, I. Suarez, M. Platten, S.-H. Chon, M. Ercanoglu, C. Lehmann, Cologne*

**\*P 175****Fetal metabolic stress disrupts immune homeostasis and induces pro-inflammatory responses in HIV-1 and cART-exposed infants**

N. Schoeman<sup>1</sup>, G. Moutloatse<sup>2</sup>, A. Harms<sup>1</sup>, H. Scherpbier<sup>3</sup>, R. Vreeken<sup>1</sup>, L. van Leeuwen<sup>3</sup>, C. Reinecke<sup>2</sup>, T. Kuijpers<sup>3</sup>, R. Berger<sup>1</sup>, T. Hankemeier<sup>1</sup>, M. Bunders<sup>4</sup>, <sup>1</sup>Leiden/Netherlands, <sup>2</sup>Potchefstroom/South Africa, <sup>3</sup>Amsterdam/Netherlands, <sup>4</sup>Hamburg

**P 176****Specialized tissue sample collectives for the DZIF Tx-cohort – a pilot study**

B. Stottmeier<sup>1</sup>, F. Lasitschka<sup>1</sup>, K. Heeg<sup>1</sup>, D. Schindler<sup>2</sup>, C. Gieger<sup>2</sup>, P. Schirmacher<sup>1</sup>, <sup>1</sup>Heidelberg, <sup>2</sup>Munich

**\*P 177****Maßnahmen zur Prävention der Postsplenektomie-Sepsis – Ergebnisse der prospektiven Freiburger Asplenie-Registerstudie**

L. Bechet<sup>1</sup>, C. Theilacker<sup>1,2</sup>, B. Lange<sup>1</sup>, K. Stete<sup>1</sup>, M. Müller<sup>1</sup>, M.-F. Juzek-Küpper<sup>1,3</sup>, I. Joost<sup>1</sup>, W. Kern<sup>1</sup>, S. Rieg<sup>1</sup>, <sup>1</sup>Freiburg, <sup>2</sup>Paris/France, <sup>3</sup>Aachen

**\*P 178****Host factors of primary CMV infection in patients after kidney transplantation**

C. Sommerer<sup>1,2</sup>, M. Neuenhahn<sup>1</sup>, C. Falk<sup>1,3</sup>, T. Giese<sup>1,2</sup>, <sup>1</sup>Munich, <sup>2</sup>Heidelberg, <sup>3</sup>Hanover

**\*P 179****Is CD32 a marker of infected cells and can be used to characterize the HIV reservoir?**

M. Wittner, G. Dunay, S. Kummer, V. Schlicker, A.-D. Hüfner, O. Degen, J. Eberhard, J. Schulze zur Wiesch, Hamburg

**P 180****Biomarker analysis of a Nigerian Lassa Fever cohort**

L. Oestereich<sup>1</sup>, E. Speranza<sup>2</sup>, D. Wozniak<sup>1</sup>, J. Port<sup>1</sup>, B. Becker-Ziaja<sup>3</sup>, E. Pallasch<sup>1</sup>, S. Bockholt<sup>1</sup>, D. Asogun<sup>4</sup>, E. Ogbaini-Emovon<sup>4</sup>, M. Pahlmann<sup>1</sup>, J. Connor<sup>2</sup>, C. Munoz-Fontela<sup>1</sup>, S. Günther<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Boston/USA, <sup>3</sup>Berlin, <sup>4</sup>Irrua/Nigeria

**\*P 181****Immune monitoring-supported treatment of a pediatric patient with sequential GvHD, acute rejection and CMV infection following lung transplantation**

C. Falk, N. Schwerk, C. Müller, I. Tudorache, K. Daemen, J. Keil, C. Neudoer, G. Hansen, A. Haverich, G. Warnecke, Hanover

**\*P 182****Fast Point of Care Testing for Common Uropathogens and Antibiotic Resistances in Urological Urine Samples to Aid Antibiotic Stewardship**

M. Fritzenwanker<sup>1,2</sup>, M. Grabitz<sup>1,2</sup>, O. Schwengers<sup>1,2</sup>, P. Hrouska<sup>1</sup>, B. Arnetz<sup>1</sup>, C. Imirzalioglu<sup>1,2</sup>, F. Wagenlehner<sup>1,2</sup>, T. Chakraborty<sup>1,2</sup>, <sup>1</sup>Gießen, <sup>2</sup>Gießen-Marburg-Langen,

**P 183****Lymphocyte Homing and Transmission in acute Lassa Fever**

J. Port<sup>1</sup>, D. Wozniak<sup>1</sup>, M. Rottstegge<sup>1</sup>, E. Ogbaini-Emovon<sup>2</sup>, S. Günther<sup>1</sup>, L. Oestereich<sup>1</sup>, C. Muñoz-Fontela<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Irrua/Nigeria

**P 184****Berlin's Fast Track Cities Initiative – Where are we now?**

D. Schmidt, C. Kollan, M. an der Heiden, H. Jessen, B. Gunsenheimer-Bartmeyer, V. Bremer, Berlin

**P 185****A blind passenger rat in an aircraft: Establishment of a workflow for multiple pathogen detection**

E. Heuser<sup>1</sup>, F. Doss<sup>2</sup>, S. Holtfreter<sup>3</sup>, D. Mrochen<sup>3</sup>, A. Zautner<sup>4</sup>, R. Ryll<sup>1</sup>, M. Beer<sup>1</sup>, R. Ulrich<sup>1</sup>, <sup>1</sup>Greifswald-Insel Riems, <sup>2</sup>Berlin, <sup>3</sup>Greifswald, <sup>4</sup>Göttingen

**\*P 186****HLA-E allelic variants impact on occurrence of CMV infection after living renal transplantation**

H. Guberina, F. de Nardi Silva, R. Tomoya Michita, S. Doff, A. Bienholz, F. Heinemann, B. Wilde, M. Trilling, P. Horn, A. Kribben, O. Witzke, V. Rebmann, Essen

**P 187****JCV-Ausscheidung im Urin von HIV-1-infizierten Patienten**

T. Harrer, K. Korn, B. Spriewald, E. Harrer, Erlangen

**P 188****Clinical chemistry and haematology study in Lassa-fever positive patients at ISTD, Nigeria**

M. Pahlmann<sup>1</sup>, B. Becker-Ziaja<sup>2</sup>, L. Oestereich<sup>1</sup>, R. Krumkamp<sup>1</sup>, E. Pallasch<sup>1</sup>, D. Adomeh<sup>3</sup>, Y. Ighodalo<sup>3</sup>, J. Oyakhilome<sup>3</sup>, E. Omomoh<sup>3</sup>, T. Olorok<sup>3</sup>, J. Agbukur<sup>3</sup>, E. Uyigwe<sup>3</sup>, E. Mudebonam<sup>3</sup>, D. Asogun<sup>3</sup>, S. Günther<sup>1</sup>, <sup>1</sup>Hamburg, <sup>2</sup>Berlin, <sup>3</sup>Irrua/Nigeria

**P 189****The Munich Infectious Mononucleosis (IMMUC) Study on Biomarkers and Causative Factors of Complicated and/or Protracted Symptomatic EBV Primary Infection**

L. Schulte-Hillen<sup>1</sup>, C. Meindl<sup>1</sup>, J. Geisberger<sup>1</sup>, F. Fischer<sup>1</sup>, J. Mücke<sup>1</sup>, S. Strunz<sup>1</sup>, N. Körber<sup>1</sup>, T. Bauer<sup>1</sup>, S. Fink<sup>2</sup>, M.-H. Tsai<sup>2</sup>, H.-J. Delecluse<sup>2</sup>, J. Mautner<sup>1</sup>, F. Hauck<sup>1</sup>, D. Hoffmann<sup>1</sup>, P. Luppa<sup>1</sup>, M. Steinborn<sup>1</sup>, W. Hammerschmidt<sup>1</sup>, C. Falk<sup>3</sup>, T. Schulz<sup>3</sup>, N. Rieber<sup>1</sup>, M. Steinhauser<sup>1</sup>, A. Moosmann<sup>1</sup>, D. Adhikary<sup>1</sup>, U. Draenert<sup>1</sup>, S. Eger<sup>1</sup>, A. Hapfelmeier<sup>1</sup>, A. Nieters<sup>4</sup>, U. Behrends<sup>1</sup>, <sup>1</sup>Munich, <sup>2</sup>Heidelberg, <sup>3</sup>Hanover, <sup>4</sup>Freiburg

**P 190****Epidemiology, clinical course and laboratory features of leptospirosis in returning travellers at a Northern German infectious disease center 2011 - 2017.**


T. Brehm, J. Schulze zur Wiesch, M. Addo, A. Lohse, S. Schmiedel, Hamburg

**P 191****Improvement of a tissue maceration technique for the determination of placental involvement in Schistosomiasis**

B. Schleenvoigt<sup>1</sup>, M. Holtfreter<sup>2</sup>, H. Neubauer<sup>1</sup>, T. Groten<sup>1</sup>, H. El-Adawy<sup>1</sup>, J. Pastuschek<sup>1</sup>, J. Richter<sup>2</sup>, D. Häussinger<sup>2</sup>, M. Pletz<sup>1</sup>, <sup>1</sup>Jena, <sup>2</sup>Düsseldorf

**P 192****Performing timely blood cultures for infectious patients is associated with shorter duration of therapy and reduced length of stay**

C. Luz<sup>1</sup>, J.-W. Dik<sup>1</sup>, A. Friedrich<sup>1</sup>, J. van der Palen<sup>2</sup>, S. van Assen<sup>3</sup>, P. Nannan Panday<sup>1</sup>, B. Sinha<sup>1</sup>, <sup>1</sup>Groningen/Netherlands, <sup>2</sup>Enschede/Netherlands, <sup>3</sup>Emmen/Netherlands



**A**

Addo, M. .... p. 8, p. 12  
 Adhikary, D. .... p. 31  
 Ahmed, M. .... p. 37  
 Altfeld, M. .... p. 11, p. 12  
 Anderson, C. .... p. 40  
 Andrade, C. .... p. 40  
 Aregay, A. .... p. 25  
 Autenrieth, I. .... p. 13

**B**

Bachmann, A. .... p. 38  
 Bairad, D. .... p. 26  
 Beckert, P. .... p. 39  
 Behrends, U. .... p. 43  
 Bender, J. .... p. 23  
 Berger, S. .... p. 32  
 Biehl, L. .... p. 32  
 Biniossek, L. .... p. 36  
 Bockmann, J. .... p. 27  
 Bone, S. .... p. 22  
 Bonsack, M. .... p. 29  
 Bonsignore, M. .... p. 34  
 Borgmann, S. .... p. 35  
 Both, A. .... p. 23, p. 35  
 Brehm, T. .... p. 24, p. 43  
 Breloer, M. .... p. 37  
 Breuer, J. .... p. 26  
 Brinkhoff, A. .... p. 41  
 Brönstrup, M. .... p. 10  
 Bunders, M. .... p. 42  
 Burchard, G. .... p. 12, p. 17  
 Burda, P. .... p. 40  
 Burggraf, M. .... p. 22  
 Busch, D. .... p. 11

**C**

Chaw, P. .... p. 23  
 Choy, S. .... p. 30  
 Cirnski, K. .... p. 34  
 Cuny, C. .... p. 23, p. 35

**D**

Dallenga, T. .... p. 36  
 Danisch, S. .... p. 31  
 de With, K. .... p. 16  
 Dietz, J. .... p. 25  
 Dojjad, S. .... p. 36  
 Dolff, S. .... p. 30  
 Dörpinghaus, M. .... p. 39  
 Draenert, R. .... p. 8, p. 18  
 Dreisbach, J. .... p. 18  
 Duraffour, S. .... p. 24

**E**

Eberhard, J. .... p. 11  
 Edoa, J. .... p. 38  
 Edoa, J. .... p. 38  
 Eibach, D. .... p. 36  
 Empting, M. .... p. 9, p. 22

**F**

Falgenhauer, L. .... p. 23  
 Falk, C. .... p. 42  
 Farowski, F. .... p. 13  
 Fätkenheuer, G. .... p. 18  
 Fischer, J. .... p. 15, p. 33  
 Fischer, T. .... p. 30  
 Fölsch, U. .... p. 16  
 Ford, C. .... p. 32  
 Forstner, C. .... p. 35  
 Freinberger, F. .... p. 22  
 Fritzenwanker, M. .... p. 42

**G**

Gellhorn Serra, M. .... p. 31  
 Ghosh, H. .... p. 24  
 Giehler, F. .... p. 26  
 Giese, T. .... p. 42  
 Grin, I. .... p. 32  
 Grobusch, M. .... p. 17  
 Grote-Gálvez, R. .... p. 36  
 Grützner, E. .... p. 25  
 Guberina, H. .... p. 11, p. 43  
 Gunesch, A. .... p. 25  
 Gutschmann, T. .... p. 38  
 Gwozdziński, K. .... p. 24

**H**

Haake, K. .... p. 38  
 Hacker, J. .... p. 16  
 Hagel, S. .... p. 15  
 Hammann, P. .... p. 16  
 Hansen, J. .... p. 33  
 Hanses, F. .... p. 15, p. 18  
 Hardtke, S. .... p. 10  
 Harrer, T. .... p. 43  
 Hauser, A. .... p. 9  
 Heckel, S. .... p. 29  
 Heitmann, A. .... p. 22  
 Hennessen, F. .... p. 34  
 Herold, S. .... p. 5, p. 16  
 Higgins, P. .... p. 22  
 Hilgenfeld, R. .... p. 10, p. 27  
 Hofer, S. .... p. 8  
 Hoffmann, R. .... p. 8  
 Hoffmann, V. .... p. 29  
 Holler, E. .... p. 13  
 Hölscher, C. .... p. 5, p. 11, p. 27  
 Hölzemer, A. .... p. 5, p. 15, p. 28  
 Hölzl, F. .... p. 5, p. 13  
 Holzmann, T. .... p. 14  
 Hörauf, A. .... p. 17, 37  
 Horn, C. .... p. 41  
 Horstmann, R. .... p. 19

**I**

Imirzalioglu, C. .... p. 14

**J**

Jahn, D. .... p. 33  
 Jakob, C. .... p. 41  
 Jansen, S. .... p. 40  
 Jansen, St. .... p. 41  
 Jarynowski, A. .... p. 34  
 Jorge, A. .... p. 26  
 Jung, N. .... p. 15

**K**

Karakose, H. .... p. 39  
 Kay-Fedorov, P. .... p. 27  
 Kern, W. .... p. 14  
 Klarmann-Schulz, U. .... p. 40

Klein, F. .... p. 10  
 Klimka, A. .... p. 28  
 Klingeberg, A. .... p. 41  
 Klöckner, A. .... p. 9  
 Knops, E. .... p. 9  
 Koch, T. .... p. 11  
 Koeppel, M. .... p. 13  
 Kokesch-Himmelreich, J. .... p. 40  
 Kompenhans, J. .... p. 41  
 Konsten, S. .... p. 38  
 Koppe, U. .... p. 34, p. 35  
 Körner, C. .... p. 32  
 Korth, J. .... p. 28  
 Krähling, V. .... p. 30  
 Kraus, E. .... p. 26  
 Kreamer, P. .... p. 17, p. 18  
 Kroidl, I. .... p. 26  
 Krome, A. .... p. 37  
 Krönke, M. .... p. 9  
 Krumkamp, R. .... p. 17  
 Kühn, A. .... p. 32  
 Kupke, A. .... p. 31

**L**

Lange, B. .... p. 37  
 Lange, C. .... p. 18  
 Layer, F. .... p. 24  
 Leggewie, M. .... p. 32  
 Lehmann, C. .... p. 10, p. 15  
 Lender, S. .... p. 38  
 Leszczczyk, C. .... p. 38  
 Lohse, A. .... p. 8, p. 16  
 Lühken, R. .... p. 37  
 Luz, C. .... p. 43

**M**

Malainou, C. .... p. 25  
 Maurer, F. .... p. 14  
 May, J. .... p. 8  
 Meier, M. .... p. 29  
 Mellinghoff, S. .... p. 28  
 Merker, M. .... p. 24  
 Mertins, S. .... p. 23  
 Michel, F. .... p. 26  
 Mohr, V. .... p. 37  
 Montoya-Díaz, E. .... p. 11  
 Muenchhoff, M. .... p. 28

Mühlen, S. .... p. 33  
Müller, C. .... p. 25  
Müller, R. .... p. 11, p. 16  
Müller, T. .... p. 26

## N

Nehls, C. .... p. 33  
Nelson, E. .... p. 29  
Ni, Y. .... p. 10  
Niemann, S. .... p. 12, p. 17  
Noll, J. .... p. 39  
Nordmann, P. .... p. 8  
Nürnberger, C. .... p. 31

## O

Oestereich, L. .... p. 26, p. 42  
Olbrich, H. .... p. 31  
Olbrich, L. .... p. 37  
Olearo, F. .... p. 35

## P

Pagel, J. .... p. 13  
Pahlmann, M. .... p. 43  
Paulowski, L. .... p. 33  
Peschel, A. .... p. 35  
Pfeifer, Y. .... p. 24  
Pinkenburg, O. .... p. 28  
Platten, M. .... p. 10  
Pohlentz, G. .... p. 33  
Port, J. .... p. 42  
Portugal, S. .... p. 18  
Potgieter, T. .... p. 26  
Protzer, U. .... p. 26

## R

Rachow, A. .... p. 36  
Rafiei Hashtchin, A. .... p. 30  
Rausch, M. .... p. 23  
Reinold, J. .... p. 31  
Rieg, S. .... p. 18, p. 42  
Ritter, K. .... p. 27  
Rohde, A. .... p. 34  
Rolling, T. .... p. 17  
Rösler, U. .... p. 16  
Roth, L. .... p. 39

Rottstegge, M. .... p. 11  
Ruibal, P. .... p. 28  
Rybniker, J. .... p. 28, S. 38

## S

Salzberger, B. .... p. 18  
Scheiber, C. .... p. 33  
Schindler, D. .... p. 29  
Schleenvoigt, B. .... p. 43  
Schlott, F. .... p. 33  
Schmidt, D. .... p. 43  
Schmidt, R. .... p. 29  
Schneider, J. .... p. 15  
Schneider, T. .... p. 8  
Schneidewind, A. .... p. 15, p. 18  
Schnettler, E. .... p. 32  
Schober, K. .... p. 30  
Scholten, M. .... p. 27  
Schughart, K. .... p. 26  
Schulze, M. .... p. 34  
Schütz, M. .... p. 13  
Schwarze, L. .... p. 26  
Schwengers, O. .... p. 24  
Seidel, D. .... p. 9  
Seifert, H. .... p. 14  
Seybold, U. .... p. 15, p. 18  
Sierra, S. .... p. 24  
Sinha, B. .... p. 14  
Slavetinsky, C. .... p. 28  
Slevogt, H. .... p. 34  
Solbach, W. .... p. 12  
Sommerer, C. .... p. 29  
Song, Y. .... p. 40  
Stecher, M. .... p. 25  
Stellbrink, H. .... p. 12  
Stottmeier, B. .... p. 42  
Strauss, C. .... p. 40  
Streeck, H. .... p. 12  
Struck, N. .... p. 40  
Struve, C. .... p. 27  
Stubbe, H. .... p. 30  
Suárez, I. .... p. 15

## T

Tacconelli, E. .... p. 14, p. 16  
Tergast, T. .... p. 41  
Theobald, S. .... p. 31

Thye, T. .... p. 17  
Toikkanen, S. .... p. 34  
Tsakmaklis, A. .... p. 29

## U

Ulrich, R. .... p. 43

## V

Vehreschild, M. .... p. 13  
Volz, A. .... p. 20, p. 31  
von Hahn, T. .... p. 10

## W

Walter, K. .... p. 39  
Wanker, M. .... p. 41  
Weissinger, E. .... p. 29  
Wichers, J. .... p. 39  
Wieler, L. .... p. 12, p. 16  
Wienhold, S. .... p. 22  
Wilde, B. .... p. 30  
Willmann, M. .... p. 14  
Witt, S. .... p. 37  
Wittner, M. .... p. 42  
Witzke, O. .... p. 11  
Wunderlich, J. .... p. 39

## X

Xanthopoulou, K. .... p. 14

## Z

Zhang, L. .... p. 27  
Ziegler, U. .... p. 10  
Zipperer, A. .... p. 13

